No retraction, correction or concern found when last checked on Oct 21, 2026.

Personalized medicine in psychiatry: problems and promises

Uzoezi Ozomaro, Claes Wahlestedt, Charles B Nemeroff

BMC Medicine · 2013 · Review

Abstract

The central theme of personalized medicine is the premise that an individual’s unique physiologic characteristics play a significant role in both disease vulnerability and in response to specific therapies. The major goals of personalized medicine are therefore to predict an individual’s susceptibility to developing an illness, achieve accurate diagnosis, and optimize the most efficient and favorable response to treatment. The goal of achieving personalized medicine in psychiatry is a laudable one, because its attainment should be associated with a marked reduction in morbidity and mortality. In this review, we summarize an illustrative selection of studies that are laying the foundation towards personalizing medicine in major depressive disorder, bipolar disorder, and schizophrenia. In addition, we present emerging applications that are likely to advance personalized medicine in psychiatry, with an emphasis on novel biomarkers and neuroimaging.

Full text

From PubMed Central, U.S. National Library of Medicine, as current on Oct 21, 2026. Paragraph numbers are ours, so an answer can point at one.

Introduction

1The foundation of personalized medicine centers on the assumption that an individual’s unique characteristics play a significant role in tailoring their therapies. Such characteristics include: genetic alterations and epigenetic modifications, clinical symptomatology, observable biomarker changes, and environmental factors. The goals of personalized medicine are to predict the individual’s susceptibility to disease, achieve an accurate diagnosis, and result in an efficient and favorable response to treatment (Figure 1). Although there are clearly some very successful examples of personalized medicine, especially in oncology, relatively few such examples exist in psychiatry. In this review, we summarize an illustrative selection of the advancements toward personalizing medicine in major depressive disorder (MDD), bipolar disorder (BD), and schizophrenia (SZ). We also discuss some new approaches currently being used and how they are likely to affect the field in the years to come.

Genetics

2One major expectation of personalized medicine is the ability to determine susceptibility or protective factors imparted through genetic change. Interestingly, in the era of genome-wide association studies (GWAS), the majority of replicable findings do not pinpoint common genes underlying susceptibility or protection from disease; instead, our current understanding centers primarily on rare genetic variants, although a number of common variants have furthered understanding as well. However, both common and rare variants account for relatively small percentages of heritability, and far greater percentages are still attributed to ‘missing heritability’. Of the diseases reviewed in this report, no variation confers an autosomal dominant mendelian inheritance typical of Huntington’s disorder; moreover, no single genetic change has shown an effect on heritability percentage that is in double digits. Nonetheless, there have been seminal genetic findings, each deepening our understanding of the major psychiatric illnesses. A sample of such findings in MDD, BD, and SZ is given below.

Genetics: major depressive disorder

3MDD has a strong genetic component, with an estimated 40 to 70% of the risk for developing MDD thought to be genetic. Prominent findings in susceptibility studies of MDD include several polymorphisms in the serotonergic system, and in various elements of the hypothalamic-pituitary-adrenocortical (HPA) axis.

4Genes involved in the serotonergic neural system have been intensively scrutinized in candidate gene and linkage studies in MDD for a number of reasons: this system is a major target of several antidepressants, and patients with MDD have alterations in multiple components of the serotonin system. Polymorphisms and variable number tandem repeat regions (VNTR) in the 5-hydroxytryptamine (5HT; serotonin) transporter (5-HTT) gene have been associated with development of MDD. In 1996, Ogilvie and colleagues identified three novel alleles of a 5-HT VNTR region, and identified an association between the nine-copy VNTR allele and risk for developing MDD. In a group of 466 German patients with MDD and 836 controls, Hoefgen et al. reported a significant increased frequency of a 44-base pair insertion/deletion polymorphism in the 5′ promoter region of the 5-HTT gene (5-HT transporter-linked polymorphic region; 5-HTTLPR) in patients with MDD relative to controls. Furthermore, this 5-HTTLPR polymorphism has been studied extensively both in the relationship between MDD and environmental factors and in the pharmacologic response to treatment (as discussed in the sections on ‘Environmental factors’ and ‘Prediction of treatment response,’ respectively).

5A rate-limiting enzyme involved in serotonin synthesis, tryptophan hydrolylase (TPH), has been implicated in susceptibility for MDD by a number of reports, although attempts at replication have shown discordant findings. Homologs 1 and 2 of the TPH gene (TPH1 and TPH2, respectively), have both been associated with MDD susceptibility. Although both TPH1 and TPH2 are involved in serotonin synthesis, their distribution is markedly different. TPH1 is found primarily in the periphery, with effects on melatonin synthesis, hemostasis, and immune system function. Conversely, TPH2 is expressed in the CNS, with central effects on sleep, aggression, food intake, and mood. Two groups analyzed TPH1 single-nucleotide polymorphism (SNP) and haplotype differences between participants with depression and control participants. In the former study, Nash et al. related quantitative phenotypes of depression in a community-based sample of 119 sibling groups to genetic alterations in TPH1, and identified a significant association between MDD susceptibility and a microsatellite downstream of TPH1. In the latter study, Gizatullin et al. conducted a genetic screen of 228 patients with MDD and 253 healthy controls, and identified six haplotypes that were associated with MDD.

6With respect to TPH2, Zill et al. identified two SNPs (rs1386494 and rs1843809) associated with MDD in a sample of 300 Caucasian patients with MDD and 265 healthy controls. Subsequently, Zhang et al. searched for a novel loss-of-function mutation, G1463A, which they had identified and characterized in the previous year in sample of 87 patients with MDD and 219 controls. The authors found that this mutation was significantly more common in patients with MDD than in controls, and suggested that defects in brain serotonin synthesis may be an important contributor to MDD susceptibility. A subsequent study by Garriock et al. failed to replicate these findings in a population similar in ethnicity and gender distribution to that of Zill et al. Serretti et al. evaluated TPH2 SNPs in MDD, BD, and SZ in Korean psychiatric inpatients and controls; their findings suggested that TPH2 SNPs are not associated with MDD, BD, or SZ. In a meta-analysis of TPH2 genetic polymorphisms and MDD, Gao et al. examined 74 TPH2 SNPs published through the end of October 2011, and using fixed-effects modeling, they found that two SNPs, rs4570625 and rs17110747, were associated with MDD susceptibility. The relationship between SNP rs4570625 and MDD was more robust, remaining significant using more conservative random-effects calculations. Notably, this SNP was not one of the SNPs reported in the Zill et al. or Zhang et al. studies, although there have been later reports suggestive of a minor role for rs4570625 in MDD as well as in SZ, panic disorder, obsessive-compulsive disorder, and attention-deficit hyperactivity disorder.

7For almost five decades, hyperactivity of the HPA axis has been reported, and this is suggested to be contributory to depressive symptomatology. Accordingly, the components of the HPA axis provides numerous genes that might be associated with risk for MDD, including, but not limited to, a key component of the glucocorticoid receptor complex, FK506-binding protein 5 (FKBP5), corticotropin-releasing hormone receptor 1 (CRHR1) and corticotropin-releasing hormone-binding protein (CRHBP). In 2004, Binder and colleagues evaluated several genes that might be responsible for the HPA hyperactivity characteristic of depression. They identified SNPs in FKBP5 associated with increased recurrence of MDD episodes and to a more rapid therapeutic response to antidepressant therapy (discussed in the section ‘Prediction of treatment response’). A 2009 study by Tatro et al. genotyped two SNPs in FKBP5, rs3800373 and rs1360780, in 60 frozen brain samples distributed over five clinical groups: MDD, MDD with psychosis, HIV-positive with MDD, and HIV-positive and HIV-negative controls. The rs3800373-CC genotype was found significantly more frequently in the MDD and MDD with psychosis groups than would be expected based on published allelic frequencies. The authors also reported that rs1360780 allele frequencies differed significantly from the expected allelic frequencies in the MDD and MDD with psychosis groups. Using a sample of 155 European adolescents with MDD from the TORDIA (Treatment of SSRI (selective serotonin reuptake inhibitor)-Resistant Depression in Adolescents) trial, Brent et al. provided preliminary reports of two FKBP5 genotypes (rs1360780-TT and rs3800373-GG) significantly associated with suicidal events.

8CRHR1 codes for a G-protein-coupled receptor involved in the regulation of the HPA axis by mediating the effects of corticotropin-releasing hormone (CRH). Raised levels of CRH in regional brain and cerebrospinal fluid (CSF) are a consistently replicated finding in patients with depression, and is also seen in suicide victims, rendering CRHR1 an attractive candidate gene for MDD susceptibility. In 2006, Liu et al. identified three SNPs in CRHR1, which were significantly more common in a group of 206 Han Chinese patients with MDD compared with 195 controls matched for age, gender and ethnicity. Subsequently, Papiol et al., compared CRHR1 SNP frequencies in 159 Spanish outpatients with MDD and 96 healthy controls, and found an association between the CRHR1 SNP rs110402 and early age of MDD onset. This SNP was also associated with increased risk for a seasonal pattern of illness. Following these findings, Lekman et al. analyzed clinical data from 1,809 outpatients with MDD and a collection of 739 ‘Black’ and ‘non-Hispanic White’ ethnically matched controls enrolled in the STAR*D (Sequenced Treatment Alternatives to Relieve Depression) study. These authors found that the SNP rs1360780 was associated with MDD susceptibility in the non-Hispanic White sample, and the SNP rs4713916 was associated with disease remission to citalopram in the overall patient sample.

9A consistent finding that clearly contributes to the HPA axis hyperactivity in MDD is hypersecretion of CRH. The CRH-binding protein (CRHBP) regulates the availability of CRH, both centrally and in the systemic circulation, which modulates HPA axis activity. SNPs in CRHPB were first associated with MDD in a case–control study conducted in a Swedish population. Claes et al. examined 89 Swedish patients with recurrent MDD and 88 control samples matched for age, gender and ethnicity, and found two SNPs that were marginally associated with MDD. The authors reported one haplotype block comprised of the CRHPB SNPs s02-TT, s11-TT, and s14-T, whose presence significantly increased susceptibility to MDD. In 2007, Van Den Eede et al. sought to replicate the CRHBP Swedish study findings in an extended Swedish sample, and in a larger and ethnically distinct sample (Belgian population). They analyzed 317 patients with MDD and 696 controls, but were unable to detect any statistically significant association (capable of withstanding correction for multiple testing) between the CRHBP SNPs in either the extended Swedish sample or Belgian sample.

Genetics: bipolar disorder

10Evidence from family, twin, and adoption studies show that BD is highly heritable, with genetic variables estimated to account for 60 to 85% of risk. Efforts to discover the genetic sources for BD risk have led to innumerable linkage studies, some of which have identified promising susceptibility loci. However, these linkage studies have been fraught with inconsistent replication and indeterminate genetic causes of increased linkage signal. Hence, there have been increasing efforts toward association studies. As with MDD, genes of the HPA axis have been probed for candidates increasing susceptibility to BD. Willour et al. genotyped FKBP5 SNPs in a family sample of 317 BD pedigrees and 554 affected offspring. They found evidence for an association with BD for five SNPs (rs4713902, rs7757037, rs9296158, rs3800373, and rs9380525), with rs4713902 showing the most robust signal (P= 0.0001). Furthermore, Willour and colleagues identified four SNPs (rs1043805, rs3800373, rs9296158, and rs1360780) in covariate-based analyses that showed differential association with BD depending on the covariates of attempted suicide and/or the number of depressive episodes. However, other studies were unable to replicate the findings of association of BD with FKBP5. Subsequent GWAS in BD have contributed modest evidence of BD susceptibility attributable to SNPs in FKBP5.

11Many candidate genes have been derived from the dopaminergic, serotonergic, and noradrenergic systems, based on the evidence for a role of these circuits in BD pathogenesis. In particular, the genes encoding 5-HTT, monoamine oxidase A (MAOA) and catechol-O-methyltransferase (COMT) have generated both positive and negative association findings with BD. However, there is no conclusive evidence for indisputable association of any of these genes with BD susceptibility. Circadian rhythm disturbances are commonly seen in BD, which has led to multiple studies of association between circadian rhythm genes and BD. The genes coding for aryl hydrocarbon receptor nuclear translocator-like BmaL1 (ARNTL) and circadian locomotor output cycles kaput (CLOCK) are two genes partially responsible for control of the internal circadian clock in the suprachiasmatic nucleus of the hypothalamus. Both of these genes have been identified in association studies of BD. For example, Mansour et al. compared 234 Caucasian individuals with BD with 180 community-based controls in a BD association study. The authors genotyped 44 SNPs from eight circadian rhythm genes: ARNTL, CLOCK, Period 1, 2, and 3 (PER1, PER2, PER3), cryptochrome 1 and 2 (CRY1 and CRY2) and TIMELESS. They found modest associations with SNPs for ARNTL and TIMELESS, although they cautioned that additional studies are necessary to corroborate the findings. Shi et al. conducted an association study of 10 circadian genes using the Sibling-Transmission Disequilibrium Test (sib-tdt) in an extended family collection (composed of 70 trios and 237 quads) in BD, and identified nominally significant association of three SNPs near or within the CLOCK gene; however, these associations did not survive correction for multiple testing.

12GWAS in BD have identified four genes for further study that had SNPs of genome-wide statistical significance: calcium channel, voltage-dependent, L type alpha 1C subunit (CACNA1C), ankyrin 3 (ANK3), neurocan (NCAN) and odd Oz/ten-m homolog 4 (ODZ4). Although not significant at the genome-wide level, spectrin repeat containing, nuclear envelope 1 (SYNE1), has been recently associated with BD and with recurrent MDD. Green et al. tested SYNE1 SNP rs9371601 in 1,527 subjects with BD and compared them with 1,579 non-psychiatrically screened controls, finding evidence for the association of the SNP with BD (P= 0.0095). Furthermore, they identified a significant association between the SNP and recurrent MDD in a sample of 1,159 subjects with recurrent MDD compared with 2,592 controls (P= 0.032). SYNE1 codes for Nesprin-1, a protein comprising part of the scaffolding that links the nucleoskeleton to the cytoskeleton (LINC). The association findings in SYNE1 relating to BD and to MDD are likely to spark subsequent genetic and functional studies.

Genetics: schizophrenia

13With estimates of heritability of 50 to 80%, SZ is one of the most heritable of the disorders discussed in this paper. Innumerable candidate gene studies and more than a handful of GWAS have contributed to the impression that SZ, despite its high heritability, is genetically complex, probably with a large polygenic component explaining a substantial amount of susceptibility. In fact, the International Schizophrenia Consortium (ISC) tested a polygenic model for SZ by summarizing nominally significant associations in their GWAS data into quantitative scores. They then related these derived scores to disease states in three large, independent target samples. From these analyses, the ISC concluded that one-third of genetic susceptibility for SZ lies in the collective effect of hundreds or thousands of common polygenic variants, each contributing small effects. GWAS are poised to reveal such variants, and the results of the SZ GWAS are largely in agreement with the ISC assessment. Three comprehensive analyses of GWAS data from the ISC, Molecular Genetics of Schizophrenia (MGS) and the Schizophrenia Genetics Consortium (SGENE) have implicated a few discrete genes with odds ratios in the range of 0.73 to 1.23. These analyses also implicated the genome region (between 26 and 33 million bp) containing the major histocompatibility complex (MHC), a group of genes that encodes proteins necessary for the immune system to recognize foreign substances. Clarifying the relationship between the MHC genes and SZ continues to be an area of active research.

14GWAS and linkage studies have homed in on possible SZ-associated genes and genetic regions outside of the MHC region that have garnered interest, including the zinc finger 804A (ZNF804A) gene. The 2008 study of O’Donovan et al. GWAS identified 12 loci with ‘moderately strong’ (P<10-5) evidence for association in their primarily European-ancestry sample of 479 SZ and 2,937 controls. Subsequently, one SNP within the intron of the ZNF804A gene, rs1344706, remained significant in their larger replication samples (6,666 SZ subjects and 9,897 controls, including 1,782 Chinese and Japanese SZ subjects, and 1,865 controls) at the more stringent ‘strong’ threshold of P<5 × 10-7 (P = 1.61 × 10-7) although not at genome-wide significance threshold (P<7.2 × 10-8). The authors then broadened their phenotype to include BD, and found a strengthening of this association beyond the genome-wide significance threshold (P = 9.96 × 10-9). Several independent replication studies identified at least nominal associations between ZNF804A and SZ. A 2010 case–control study by Riley et al., compared 1,021 Irish subjects with SZ or poor-outcome schizoaffective disorder with 626 Irish control subjects, and reported nominally significant association between SZ and ZNF804A rs1344706 (P = 0.0227) and two other ZNF804A SNPs (rs17508595 at P = 0.0230 and rs7597593 at P = 0.0013). Steinberg and colleagues (2011) reported an association between rs1344706 and SZ (P = 0.0029) and SZ plus BD (P = 0.00065) in their sample (European ancestry with Chinese in follow-up study). Notably, when stratified by population, only two of the thirteen ethnicities, that is, Danish and Russian, exhibited a significant association between rs1344706 and SZ. Zhang et al. conducted a population case–control study and a family-based study in a Han Chinese population. They reported a significant over-representation of the T allele of rs1344706 in their SZ population relative to controls in the population-based study (P = 0.00083) and a trend toward positive association in their trios (P = 0.058). In the wake of these findings, Williams et al. performed a meta-analysis of the data from the discovery GWAS along with data from thousands of additional European-ancestry samples from in-house sources, five GWAS (ISC, MGS, SGENE-plus, the Lencz et al. GWAS, one unpublished Swedish GWAS from Sullivan and Hultman), and a handful of collaborative groups (totaling 18,309 SZ cases and 35,739 controls). The meta-analysis supported the original findings for association between rs1344706 and SZ (P = 2.5 × 10-11; odds ratio (OR) = 1.10; 95% confidence interval (CI) 1.07 to 1.14) and with SZ plus BD (P = 4.1 × 10-13; OR = 1.11; 95% CI 1.07 to 1.14). To date, ZNF804A remains one of the most promising of the GWAS findings in SZ.

15Another gene with genome-wide association with SZ is transcription factor 4 (TCF4), which is a gene important for neurodevelopment. Mutations in this gene have been linked to Pitt-Hopkins syndrome, a neurodevelopmental condition characterized by mental retardation, epilepsy, hyperventilation episodes, and distinct facial features. With respect to SZ, one TCF4 intronic SNP (rs9960767; C allele), was found to be significantly associated in a GWAS and analysis of nearly 50,000 subjects (data from SGENE-plus, follow-up samples, ISC and MGS GWAS samples) (P = 4.1 × 10-9; OR = 1.23; 95% CI 1.15 to 1.32). Steinberg et al. (2011) expanded on these findings, evaluating SNPs that had P-values of less than 1 × 10-4 in the combined sample (SGENE-plus, MGS, ISC dataset) of Stefansson et al.. In the Steinberg et al. study, an additional 9,246 Caucasian SZ samples (SZ, schizoaffective disorder, or persistent delusional disorder) and 22,356 controls were assessed, followed by analysis of another 1,014 SZ and 1,144 control samples in a subsequent follow-up. These analyses implicated the C allele of the original rs9960767 SNP in SZ, in the primary, but not in the secondary follow-up (P = 2.5 × 10-4; OR = 1.16; 95% CI 1.07 to 1.25 and P = 0.5; OR = 1.09; 95% CI 0.85 to 1.41, respectively). Considered together, the Stefansson et al. combined sample and the two follow-up studies yielded a genome-wide significant association of rs9960767-C with SZ (P = 4.2 × 10-9; OR = 1.20; 95% CI 1.135 to 1.27). In 2011, Ripke et al. completed a replication study in Caucasians that also identified association of TCF4 with SZ (P = 2.29 × 10-5), albeit with a different SNP, rs12966547 (which is not in linkage disequilibrium (LD) with rs9960767). Analysis of their replication data pooled with their discovery sample (which has significant overlap with the Stefansson et al. sample), yielded an association of genome-wide significance (P = 2.6 × 10-10). Notably, a TCF4-SZ association has also been established in a non-Caucasian population. Li et al. explored the TCF4 gene in a Han Chinese population of 2,496 subjects with SZs and 5,184 controls. Interestingly, the TCF4 SNP highlighted by Stefansson et al. is polymorphic in Caucasians, but is not polymorphic in the Chinese population. Instead of using this SNP, Li et al. substituted a nearby SNP, rs2958182 (which is in complete LD with rs9960767, and is polymorphic in the Chinese population). This group found rs2958182 to be significantly associated with SZ in their Chinese population (P = 3.64 × 10-6), which provides additional support for a TCF4-SZ association. Together, these findings continue to fuel genetic and functional exploration of TCF4 in SZ.

16Neuregulin 1 (NRG1) is a gene that is also involved in many neurodevelopmental functions, including regulation of the expression and activation of glutamate receptors, neuronal migration, and oligodendrocyte development. Mutant mice heterozygous for NRG1 (or for its receptor, ERBB4) have fewer NMDA receptors than their wild-type littermates. Moreover, they exhibit a SZ-like phenotype, which is reversible with the atypical antipsychotic drug, clozapine. Linkage studies in the 1990s and early 2000s originally highlighted the cytogenic region containing the NRG1 gene, 8p22-21, as a possible ‘schizophrenia susceptibility locus’ (SSL). A more specific gene-disease association was first suggested in a 2002 Icelandic linkage study in which a NRG1 haplotype, HapICE (composed of five SNPs and two microsatellite markers), was found significantly more often in SZ samples than in control samples. These initial findings spurred more than 60 additional studies of NRG1 as a putative schizophrenia risk gene, yielding mixed findings. By 2011, several large case–control studies (>1000 subjects) had found at least one positive NRG1-SZ association, whereas comparably sized studies found no association at all. NRG1 analyses in large family-based studies (>200 families) fared similarly, with nearly equal positive and negative association findings. Meta-analyses by Munafò and colleagues in 2005 and updated in 2008, noted a gene-level association between NRG1 and SZ, but their data did not support an association between any particular NRG1 SNP or haplotype with the disease. The results suggest that analyses at the level of the gene, rather than the level of an individual SNP, functional variant, or haplotype, might be a more reliable method of analysis.

17Over 8,000 polymorphisms spaced over more than 1,000 candidate genes have been systematically analyzed in SZ (full results of the analyses can be found in the comprehensive SZ association study database, SZGene; http://www.szgene.org). Notably, Allen et al. highlighted SNPs in 16 genes with at least nominally significant effects (OR ranging from 0.7 to 1.52): DRD2, GRIN2B, TPH1, DTNBP1, MTHFR, DRD1, APOE, DRD4, COMT, TP53, HP, DAO, SLC6A4, GABRB2, PLXNA2, and IL1B.. One of these genes receiving a great deal of attention is COMT, in part because of its known functions, and in part due to its location in the genome. The COMT gene encodes a protein responsible for the metabolic degradation of catecholamines. In addition, COMT is located on chromosome 22, within a region that when deleted causes velocardiofacial syndrome. Notably, nearly 25% of the individuals inheriting the large deletion at 22q11.21 go on to develop SZ, making the inheritance of this deletion one of the greatest risk factors for development of SZ. In 2002, Shifman et al. found a significant association between a COMT haplotype and SZ in a case–control study in Ashkenazi Jews. One 5′-UTR SNP involved in the haplotype (rs737865) has been implicated in a subsequent studies, and despite both positive and negative findings, maintains nominal significance by SZGene meta-analysis, with a modest OR of 1.06 (95% CI 1.01 to 1.11, P<0.05).

18The disrupted-in-schizophrenia (DISC) locus has also been associated with SZ after its initial characterization in a large Scottish family with high psychiatric load. The DISC locus was identified at the breakpoint of a balanced translocation between chromosomes 1 and 11. The translocation significantly segregated with a range of psychiatric illness in the family, including SZ, MDD, and BD. Further analysis showed that the translocation is in significant LD with SZ, outside of the effects of the other psychiatric illnesses (log of the odds ratio score being 3.6). Fine mapping focused further studies on two genes, DISC1 and DISC2, identified along the chromosome 1 component of the translocation. DISC1 codes for a protein known to have diverse roles, including regulation of neuronal axonal and dendritic outgrowth, cell proliferation, and cell differentiation. DISC2 is a non-protein-coding gene thought to be important in the regulation of DISC1. The majority of DISC1 family and association studies have had positive findings of a relationship between the gene and SZ. However, there have also been a number of studies which have not been able to show any significant findings. To date, there have not been any positive association studies for DISC2 and SZ despite one large association study of 1,054 Scottish individuals (328 with SZ, 726 controls), which did not find any significant associations between DISC2 SNPs and SZ.

Epigenetic modifications

19Although genetics clearly play an important role in personalized medicine, the role of epigenetics should not be overlooked. Epigenetics refers to the phenomenon of heritable changes to gene regulation caused by mechanisms that do not involve modification of the nucleotide sequence. Increasingly, it is being realized that these mechanisms are far more complex than originally envisioned, requiring adjustment of the current perspective on the central dogma of molecular biology; namely, that DNA transcribes RNA, which is subsequently translated into protein. It is estimated that approximately 98% of the human genome is not translated into protein, and these epigenetic changes occur within the framework of DNA being transcribed into both coding and non-coding RNA, with the subsequent translation of coding RNA into protein, and the concurrent regulation of each of these steps by non-coding RNA (Figure 2). Specific epigenetic mechanisms include DNA methylation, histone modification, alternative splicing, RNA editing, and non-transcriptional gene silencing via microRNAs. Epigenetic regulation has been implicated in a myriad of neural processes, from learning and memory to seizures and neurogenesis, and recently to depression, chronic stress, and various addictions.

Epigenetic modifications: major depressive disorder

20Study of the epigenetics of MDD, particularly involving DNA methylation and histone modification, has generated some interesting findings. Electroconvulsive therapy (ECT), the induction of controlled seizures to relieve depressive symptoms, can be remarkably effective in severe treatment refractory cases of depression. The effectiveness of ECT requires multiple treatments, and without continued antidepressant therapy or maintenance, nearly all patients will have a relapse of their symptoms. Epigenetic changes are thought to partially account for this phenomenon.

21In animal models of depression, chromatin remodeling of brain-derived neurotrophic factor (BDNF) promoters leads to site-specific increased BDNF transcription, a change shown to mediate susceptibility to stress in humans and in mouse models. Another notable example of epigenetic changes is seen in rats reared by mothers who exhibit especially high levels of nurturing behaviors of pup licking and grooming (LG). The authors described the adult rat offspring from high-LG mothers as being less anxious than their low-LG counterparts. The high-LG offspring also displayed corresponding measurable changes to the HPA axis (for example, increased glucocorticoid receptor mRNA and protein expression, decreased hypothalamic corticotropin-releasing factor (CRF) mRNA expression and increased sensitivity to glucocorticoid negative feedback), changes that are due, in part, to gene-expression changes that remain stable until adulthood. Of note, these gene-expression alterations are reversible with cross-fostering of rats between high-LG and low-LG mothers. Building on these principal findings, McGowan et al. explored the epigenetic regulation of a neuron-specific glucocorticoid receptor gene (nuclear receptor subfamily 3, group C, member 1; NR3C1) in human suicide victims subjected to childhood abuse. In their study, they compared post-mortem hippocampal tissue samples from 12 suicide victims with a history of childhood abuse, 12 suicide victims with no history of childhood abuse, and 12 controls (persons experiencing sudden, accidental death without a history of childhood abuse). They found that the expression of total glucocorticoid receptor mRNA was significantly lower in the abused suicide victims than in either the non-abused suicide victims or the controls. Furthermore, the level of methylation of the NR3C1 promoter sites was significantly higher in the abused suicide victims compared with the non-abused suicide victims or controls. Notably, in both of these findings, there were no significant differences between the non-abused suicide victims and the controls. The authors report that these findings are consistent with those in animal models showing epigenetic modifications of the glucocorticoid receptor leading to increased HPA responses to stress. Moreover, they speculate that early adverse life events, such as childhood abuse, may lead to epigenetic changes that contribute to risk for developing psychopathology.

Epigenetic modifications: bipolar disorder and schizophrenia

22Because many epigenetic studies of BD also include patients or tissue samples with SZ, the epigenetic studies involving both disorders are summarized here. The role of methylation in SZ has been suggested for over 50 years, when patients with SZ who were administered a methylating agent, methionine, were noted to experience exacerbation of their psychosis. Since that time, many post-mortem brain studies have focused on methylation patterns in SZ. For example, differential methylation patterns in the regulatory regions of COMT and reelin (RELN) have been found between individuals with SZ compared with controls. From a functional standpoint, dysregulation of either of these genes could feasibly result in psychopathology. COMT is an important gene for metabolizing catecholamines, while RELN encodes an extracellular matrix glycoprotein theorized to control cell-cell interactions during neuronal positioning and migration during brain development. Abdolmaleky and colleagues analyzed 115 post-mortem brain samples from the frontal lobe of individuals with BD or SZ and controls (35 samples per group). The membrane-bound (MB)-COMT promoter was hypomethylated significantly more often in the brains of individuals with SZ or BD relative to the brains of controls. Generally, methylating DNA sequences tends to decrease their transcription, and accordingly, this hypomethylation in the BD and schizophrenic brains corresponded with higher MB-COMT transcript expression than seen in the controls. The authors remarked that the resulting overexpression of MB-COMT could lead to significant increases in dopamine degradation. Moreover, the resulting hypodopaminergic state and frontal-lobe hypoactivity may be amenable to COMT-inhibitor drugs or preventative strategies to modulate methylation of the COMT promoter. Lower levels of RELN mRNA expression and protein concentrations were found in post-mortem brain samples from patients with schizophrenia relative to control brain samples, which led to investigations of whether promoter regions are differentially methylated in such patients relative to controls. In a small (n = 10) post-mortem study of schizophrenic brains compared with controls, Abdolmaleky et al. found a significant increase in DNA methylation of CpG islands in the RELN promoter in brains from individuals with SZ compared with controls. However, neither set of findings (the hypomethylation of the COMT regulatory regions and the hypermethylation of the RELN regulatory regions) have been replicated in subsequent studies.

23Some studies have suggested that epigenetic dysregulation of the 5-HT2A receptor gene (HTR2A) may contribute to the pathophysiology in SZ. The focus on HTR2A is not surprising, as it has been the subject of many studies, which have provided conflicting evidence for a small, but significant, association of an HTR2A SNP, rs6313 (c.102C>T), with SZ in European populations. This 102-nucleotide position is near the promoter region, and is thought to be a putative methylation site, which is consistent with the lower levels of 5HT2A mRNA seen with the C allele (in both patients and controls). Indeed, in a study on post-mortem human brain tissue, Polesskaya et al. reported that one of the key determinants of HTR2A expression was cytosine methylation at rs6313. Notably, this decrease in HTR2A mRNA is a property that is exaggerated in SZ. Furthermore, antipsychotic treatment decreases methylation at the 102C polymorphic site, while HTR2A mRNA expression increases. Interestingly, this SNP is in complete LD with a promoter SNP, rs6311 (c.-1438G>A), for which there is also some evidence in favor of an association with SZ in Caucasian samples (SZGene 2010 meta-analysis: OR = 1.20; 95% CI 1.07 to1.36]). Carrying the minor allele in rs6311 results in the creation of a methylation binding site for the E47 transcription activator at position −1,438, and results in the loss of a CpG binding site at position −1,439. These findings indicate how genetic alteration can trigger a chain of downstream epigenetic effects. Clearly, deciphering the effects of HTR2A gene-expression dysregulation in SZ will continue to be a rich source of study.

24Histone modification is another epigenetic mechanism hypothesized to contribute to the pathogenesis of SZ and BD. Post-mortem studies have shown increased levels of histone deacetylase, type 1 (HDAC1), an enzyme generally responsible for silencing gene expression, in the pre-frontal cortices of patients with SZ. Sharma et al. found a strong negative correlation between HDAC1 and GAD67 mRNA, which encodes an isoform of glutamate decarboxyase (GAD). Taken together, these findings provide a possible mechanism for the common observation of decreased expression of GAD, the rate-limiting enzyme involved in the synthesis of gamma-aminobutyric acid (GABA) in the brains of patients with schizophrenia or BD. Furthermore, in an animal model that used methionine to induce SZ-like behavioral abnormalities, HDAC inhibitors (HDACi) were sufficient to attenuate the behavioral abnormalities. Valproate is a mood stabilizer and a potent HDACi, whose mood-stabilizing effects in BD and SZ may be based on its epigenetic properties.

25MicroRNAs (miRNAs) are important contributors to epigenetic modifications. Specifically, miRNAs are non-coding RNA sequences that can broadly regulate gene expression post-transcription. Studies of miRNA in BD and SZ have thus far yielded somewhat inconsistent results. Perkins et al. observed the expression pattern of miRNAs in the pre-frontal cortex (PFC), and identified 16 miRNAs differentially regulated in their sample of 15 patients with SZ or schizoaffective disease, relative to their 21 control samples. Of the 16 identified miRNAs, 15 were downregulated in SZ. Studies conducted by Beveridge and colleagues in 2008 and 2010 showed miRNA dysregulation and altered miRNA biogenesis in the brains (specifically, the PFC and the subgenual superior temporal gyrus) of patients with SZ. Interestingly, many of their identified miRNAs were upregulated, and those that overlapped with the Perkins study were upregulated in the Beveridge studies but downregulated in the Perkins study. Furthermore, the identified alterations in miRNA in the Perkins study suggested a decrease in global miRNA biosynthesis whereas the 2010 Beveridge study suggested a global increase in miRNA biosynthesis in SZ. A recent study by Miller et al. explored the expression of over 800 miRNAs in the dorsolateral PFC (dlPFC) in RNA samples from 35 patients with SZ, 31 with BD, and 34 controls. The authors identified significant dysregulation in 10 miRNAs in BD and alteration of the miRNA-132 in SZ. Notably, there were no significant miRNA overlaps between BD and SZ. Further analyses, which ranked the associations of miRNA with BD or SZ by fold change and uncorrected P-values, identified six dysregulated miRNAs common to both conditions. In fact, 754 protein-coding genes are affected by two or more of these miRNAs, which is significantly higher than would be expected by chance (P<0.0001), suggesting that co-dysregulation of these targets may result in pathologic alterations in functionally overlapping molecular networks. Reliably associating miRNAs with psychiatric illness is a relatively new field of study, although there are data to suggest that other individual miRNAs may be linked with SZ and or BD (for an excellent review, see Miller and Wahlestedt).

Clinical diagnostics: endophenotypes/biological markers

26Endophenotypes are markers of an illness regardless of the phenotypic presence or absence of the illness. Because psychiatric disorders are primarily defined based on symptoms, many of which overlap between different disorders, the concept of defining endophenotypes for the disorders is an attractive one. Gottesman and Gould in 2003 discussed endophenotypes in psychiatry and outlined criteria for defining endophenotypes. The endophenotype should segregate with the illness in the population, and co-segregate with the illness within families; it should be heritable and more prevalent in affected than in unaffected families; it should not depend on whether the illness is currently clinically manifested, and finally, it should be specific to the illness and capable of being reliably measured.

27Biomarkers are measureable characteristics that reflect biologic function or dysfunction, response to a therapeutic measure, or indication of the natural progression of disease. Historically, psychiatric illnesses have been diagnosed on the basis of behavioral signs and symptoms, rather than on biomarkers, but the overwhelming evidence that severe psychiatric disorders are in fact brain diseases, has led to considerable efforts to identify and introduce biomarkers into clinical psychiatry. Current biomarkers for psychiatric illness fall into roughly three categories: metabolite levels, molecular genetics, and imaging findings. There are subtle distinctions between endophenotypes and biomarker changes, because endophenotypes are trait markers, whereas biomarkers may be state or trait markers. However, there exists substantial overlap between these two categories, and we have therefore combined discussion of each into one section.

Clinical diagnostics: major depressive disorder

28Negative mood is a central feature in MDD, and there have been a number of studies evaluating this as an endophenotype for depression. Wichers et al. conducted a study in female twin pairs, assessing the relationship between daily life negative mood bias and the lifetime diagnosis of MDD. They studied 259 twin pairs; 17.4% of the sample represented twin pairs of which one twin had a diagnosis of lifetime depression while the co-twin did not. The authors found that probands with co-twins meeting a diagnosis for lifetime depression exhibited greater negative affect responsiveness to daily life stressors. This relationship held true after controlling for proband continuous depression score, past depressive score, and exclusion of probands who were depressed at the time of the study. The authors concluded that increased negative affect reactivity is present in probands with high familial load for depression, regardless of past or current depression. Furthermore, mood-congruent memory (MCM) bias was first reported in the 1980s and has been repeatedly demonstrated in MDD and dysphoria in a multitude of recent studies.

29Similar to negative mood, anhedonia is a central feature of the MDD diagnosis and has been proposed as an endophenotype for MDD. Dryman and Eaton analyzed data from 49 individuals enrolled in the US National Institute of Mental Health Catchment Area Program (NIMH-ECA) during the period 1981 to 1985, and found that anhedonia often precedes the onset of MDD. Furthermore, some researchers have found an association between family history for depression and anhedonia in unaffected relatives. McCabe et al. used functional magnetic resonance imaging (fMRI) to compare 13 unmedicated individuals recovered from MDD with 14 healthy controls to evaluate whether deficits in the processing of reward-relevant stimuli are present in people at risk for developing MDD. Compared with the healthy controls, the recovered MDD individuals showed decreased neural response in the ventral striatum to pleasant stimuli and an increased response in the caudate nucleus to aversive stimuli. The authors suggested that patients in remission from MDD may have deficits in the neural basis of reward.

30CSF concentrations of the norepinephrine metabolite 3-methoxy-4-hydroxphenylglycol (MHPG) has long been proposed as a biomarker for suicide risk, although studies have generated conflicting findings. In a 2009 study, Galfalvi et al. completed a prospective study of the relationship between MHPG levels and suicidal behavior in 184 subjects with MDD or BD experiencing a depressive episode. They identified that lower levels of the metabolite were predictive of suicidal behavior in this population. Additionally, lower MHPG levels correlated with higher medical lethality of the future suicide attempt. The authors suggested that CSF MHPG may be useful as a biomarker for risk for short-term suicidal behavior.

31Neuroimaging findings are being increasingly proposed as endophenotypes in MDD. Ramel et al. used fMRI to compare 14 unmedicated remitted-depressed (RD) individuals with 14 matched, never-depressed (ND) individuals on a self-referent encoding/evaluation task completed before and after a sad mood challenge. For a subset of the RD group, after priming with sad mood induction, bilateral amygdala activation predicted negative recall bias. Notably, this association was not present before the sad mood priming, nor was it present in the ND group for any mood state.

Clinical diagnostics: bipolar disorder

32BDNF is a protein that contributes to synaptic plasticity and neuronal survival, and has been implicated in the pathophysiology of a number of psychiatric illnesses. Because BDNF levels in serum reportedly have high correlation (r = 0.8) with CSF levels, and are purported to cross the blood–brain barrier, BDNF is an attractive candidate for real-time study of BD mood states. Recently, two meta-analyses by Fernandes et al. and Lin probed whether serum or plasma BDNF levels could reliably serve as a state marker of mood episodes in BD. In an analysis that combined studies of BDNF levels in either serum or plasma, Lin identified that relative to controls, patients with BD in either manic or depressive states exhibited significant decreases in peripheral blood BDNF levels, and additionally, that pharmacologic treatment of manic states was accompanied by a significant increase in BDNF blood levels (plasma or serum). The Fernandes et al. meta-analysis comprised 13 case–control studies (548 patients with BD and 565 controls), and measured serum BDNF levels during each of the three BD states: mania, euthymia, and depression. The analysis showed that, relative to levels in controls, serum BDNF levels were reliably decreased during manic and depressive states, and normal in euthymia. The Fernandes group suggested that serum BDNF concentrations can be used to accurately discriminate between the depressive episodes of MDD and those of BD (the suggested cut-off of 0.26 resulted in 88% sensitivity and 90% specificity). This has significant clinical implications because the ability to distinguish between BD and MDD is extremely important, especially in view of the likelihood of antidepressant monotherapy precipitating manic episodes in patients with BD.

33Various cognitive phenotypes have also been suggested as endophenotypes for BD, including processing speed, visual learning and memory, verbal fluency, psychomotor retardation, and response inhibition. In their meta-analysis of BD endophenotype candidates, Bora et al. noted that of the 18 cognitive tests reviewed, euthymic patients with BD performed significantly more poorly than controls on all but one measure, the visual copy task. Moreover, the authors found that response inhibition is the most significant endophenotype for BD, which is significantly impaired in both patients with BD and unaffected relatives of such patients, but not in controls. Other proposed endophenotypes with strong support from their meta-analysis are verbal memory (large effect size in BD versus controls; modest effect size between relatives of patients with BD versus controls) and psychomotor retardation (moderate effect size in BD versus controls, no significant difference in relatives of patients with BD versus controls). The investigators recommended longitudinal studies to determine the relationship between cognitive impairment and brain connectivity and genetics.

Clinical diagnostics: schizophrenia

34The possibility that certain cognitive deficits should be considered as SZ endophenotypes has been supported by multiple lines of evidence. Three meta-analyses reflect efforts to interpret which cognitive domains are most consistently deficient in the SZ population relative to controls. The meta-analysis by Sitskoorn and colleagues compiled data from 37 studies, and identified nine weighted variables (broadly derived from the three domains of attention, memory, and executive function) that differed significantly in SZ subjects relative to controls. The largest effect sizes found were for deficiency in verbal memory recall and executive functioning in subjects with SZ relative to healthy controls (Cohen’s d = 0.54, 95% CI 0.43 to 0.66, P<0.0001; d = 0.51, 95% CI 0.06 to 0.50, P<0.0001). Smaller effect sizes for their other variables ranged from d = 0.28 to d = 0.38 for the remainder of the variables (in decreasing effect size): visuomotor tracking, attention/verbal memory span, verbal fluency, sustained attention, visual memory, executive function, and selective attention. Szöke et al. reported in their meta-analysis six altered cognitive variables in first-degree relatives of subjects with SZ relative to controls, with the greatest effect sizes seen for semantic and phonological verbal fluency (Hedges’ unbiased g = 0.87, 95% CI 0.64 to 1.10; g = 0.65, 95% CI 0.48 to 0.82, respectively). The remainder of the effect sizes were smaller, ranging from g = 0.26 to g = 0.49 for visuomotor speed/executive function, selective attention, and executive function (Wisconsin Card Sorting Test categories and perseverative errors). The meta-analysis by Fioravanti et al. identified five cognitive domains in which subjects with SZ performed significantly worse than controls: memory, language, attention, executive function, and IQ (with memory having the greatest standardized mean difference of −1.18 (95% CI −1.31 to−1.05, P<0.00001). In 2007, Gur et al. assessed neurocognitive function in 349 members of 35 multigenerational families with SZ and in 154 medically and psychiatrically healthy controls in an attempt to characterize a neurocognitive profile for SZ. They found that probands with SZ were the most impaired with regard to certain neurocognitive domains, the control group was the least impaired, and the unaffected relatives of the probands with SZ were impaired at an intermediate level between the other two groups. In particular, the authors reported strong genetic influences on the variability of performance on memory and emotion processing accuracy and on speed of attention. Further, because these measures were associated with SZ, they could be applied to differentiate between unaffected relatives and controls, and because they appear to be heritable, the authors proposed that they could be suitable for use as endophenotypes for genetic studies. Despite some heterogeneity between studies, others have identified cognitive deficits in individuals with SZ and their unaffected relatives compared with controls, consistent with generalized cognitive impairment in these patients and their genetically susceptible relatives.

Environmental factors: stress

35All of the reviewed psychiatric illnesses are characterized by various degrees of symptom exacerbation upon exposure to stress. Often underlying this response is dysregulation of the HPA axis, an important modulator of adaptive responses to stress. In fact, increased secretion of cortisol, one of the downstream products of the HPA axis, has been reported for decades in MDD. Upstream of cortisol in the HPA axis is corticotropin releasing hormone (CRH, also known as corticotropin releasing factor, CRF), which is both an important regulator of the HPA axis and a key regulator in many extra-hypothalamic brain areas, including the amygdala, septum, stria terminalis, and cerebral cortex. In these areas of the brain, CRH acts as a neurotransmitter, orchestrating endocrine, immune, and behavioral responses to stress. In fact, injection of CRH into the CNS of rodents produces a host of endocrine and immune changes, and results in behavioral symptoms resembling those of MDD in humans. In view of this, special attention has been given to identifying associations in HPA axis genes, in particular those affecting CRH levels. There have been numerous studies identifying SNPs in the gene coding for the CRH receptor 1 (CRHR1), which are associated with MDD. Some studies have also identified differential treatment response to antidepressant therapy with various CRHR1 haplotypes. Importantly, certain CRHR1 SNPs and haplotypes appear to modify the adult risk of MDD in individuals subjected to childhood trauma. Bradley et al. conducted a study in a group of primarily socioeconomically disadvantaged African-Americans with high rates of lifetime trauma (n = 422), to explore whether the effects of child abuse on MDD susceptibility is moderated by variation in the CRHR1 gene. Linear regression analyses identified a significant protective effect of the gene and environment (G × E) interaction between two SNP haplotypes each with three SNPs (P<0.001; rs7209436-T, rs4792887-C, rs110402-A and P<0.005; rs7209436-T, rs242924-C and rs110402-A), and with the three individual SNP components of the latter haplotype. In an independent sample of primarily Caucasian individuals (n = 299), the authors found similar findings, namely significant over-representation of the protective SNP alleles and haplotypes. Polancyzk et al. replicated the Bradley findings in a sample of English women, but could not replicate the sample when using a different measure of child abuse than the Childhood Trauma Questionnaire (CTQ) used in the Bradley study. The CRHR1 gene interaction with trauma in childhood and with MDD in adulthood has been scrutinized by two other groups, who used a dexamethasone/corticotropin-releasing hormone test (DEX/CRH) as a measure of HPA axis activity. Tyrka et al. found that two of the CRHR1 SNPs identified in the Bradley et al. study, rs110402 and rs242924, showed a significant interaction with childhood abuse and prediction of cortisol response to the DEX/CRH challenge. Similarly, Heim et al. used the DEX/CRH measure, and found the same relationship, although only in men, and suggested that the nature of the type of abuse experienced is crucial because in their sample, men experienced more physical abuse than did women.

36In addition to its contribution to susceptibility for MDD and to epigenetic alterations in MDD (see ‘Genetic and epigenetics of MDD’) the serotonin transporter gene 5-HTT polymorphism, 5-HTTLPR, has been implicated in G × E interactions. Specifically, Caspi et al. evaluated the relationship between MDD, the 5-HTTLPR genotype, and stressful life events over five years in a group of 847 Caucasian non-Maori individuals involved in the Dunedin Multidisciplinary Health and Development Study prospective longitudinal study. The authors used a moderated regression framework with sex as a covariate, and reported that the effect of stressful life events was significantly stronger in individuals carrying the short allele than in those carrying the long allele (P = 0.02). Moreover, they identified that childhood maltreatment predicted adult depression in individuals carrying the short allele but not in individuals homozygous for the long allele (P = 0.05).

Environmental factors: in utero exposure

37Much of the work focusing on in utero exposure to psychiatric illness has centered on SZ, with limited study of BD. Monozygotic twins are concordant for SZ in approximately 45% of cases, which indicates a potentially large contribution from environmental factors in the development of the illness. Some studies have sought data from in utero and perinatal environmental exposures for potential explanations as to how monozygotic twins can be discordant for SZ. In 1967, the NIMH completed its first study on monozygotic twins discordant for SZ, examining 14 pairs of monozygotic twins, and summarizing published reports from 100 pairs of monozygotic twins discordant for SZ. Comparing available information on the twin pairs illustrated that the SZ-affected twin was more likely to have sustained birth complications (index twin: control twin (I:C) = 4.0, n = 30), including perinatal asphyxia (I:C = 4.0; n = 15), and to be more than twice as likely to be the lighter-weight twin (I:C = 2.1; n = 61; P<0.01). These data laid the groundwork for many additional examinations of prenatal and perinatal insults. Cannon et al. conducted a meta-analysis of eight prospective population-based studies of obstetric complications and SZ, and identified three groups of complications that significantly increased the risk for SZ: 1) pregnancy complications, including bleeding, Rhesus factor incompatibility, diabetes, and pre-eclampsia, 2) abnormal fetal growth and development, including low birth weight, congenital malformations, and reduced head circumference, and 3) delivery complications, including uterine atony, asphyxia, and emergency Cesarean section. Although many of the independent characteristics had modest effect sizes, with OR≥2 (bleeding, Rhesus factor incompatibility, pre-eclampsia, reduced head circumference, and asphyxia), other characteristics showed sizeable ORs: diabetes in pregnancy (OR = 7.76, 95% CI 1.37 to 43.90, P<0.03), low birth weight (< 2000g; OR = 3.89, 95% CI 1.40 to 10.84, P = 0.009), emergency Cesarean section (OR = 3.24, 95% CI 1.40 to 7.50, P = 0.006), congenital malformations (OR = 2.35, 95% CI 1.21 to 4.57, P<0.02), and uterine atony (OR = 2.29, 95% CI 1.51 to 3.50, P<0.001). By contrast, another study found no robust evidence for an association between BD and obstetric complications.

38Other in utero exposures theorized to be involved in SZ are maternal influenza and maternal stress. Following an influenza pandemic in 1957, studies in Finland, England and Wales, and the USA suggested a possible association between SZ development and prenatal exposure to the influenza virus. However, subsequent studies produced conflicting findings. A 2010 meta-analysis of 13 studies of SZ and maternal influenza exposure following the 1957 pandemic could not identify an association risk for SZ and prenatal influenza exposure. The relationship between prenatal exposure to maternal stress and SZ was also analyzed by meta-analysis after individual studies produced equivocal findings. The meta-analysis by Selten et al. could not identify a statistically significant association, despite querying various forms of maternal stress (wars, spousal demise, natural disasters, and undesired pregnancies).

Role of genetic alteration in drug-metabolizing enzymes

39Many of the SNPs reviewed above and many others have been associated with predicting treatment response (both in terms of therapeutic efficacy and side-effect profile) to a pharmacologic intervention. Beyond the effects specific to particular illnesses or drugs are the genetic changes in drug-metabolizing genes that underlie differential response to pharmacologic agents. These genetic changes will be reviewed first, followed by specific polymorphisms in non-drug-metabolizing enzymes (non-DME) and their relationship to specific psychiatric illnesses.

40The most studied group of drug-metabolizing enzymes (DME) in psychiatry are the cytochrome P450 (CYP) enzyme family. CYP enzymes are expressed predominantly in the liver, although they are also found in many extra-hepatic locations, including in the brain, where their levels are approximately 0.5 to 2% of those in the liver. Moreover, the genes coding for the CYP enzyme family are highly polymorphic, and the effects of many of the genetic differences contribute to differential metabolism of psychotropic agents. DME phenotypes are broadly grouped into four categories based on genotype effect on enzyme activity: 1) poor metabolizers (PM), 2) intermediate metabolizers (IM), 3) extensive metabolizers (EM), and 4) ultra-rapid metabolizers (UM). CYP2D6 is an important member of the CYP enzyme family, because it is responsible for metabolizing nearly 50% of the most commonly prescribed psychotropics, and evidence in animal models indicates its involvement in the biosynthesis of dopamine and 5-HT. It is also highly polymorphic, with 7% of Caucasians falling into the CYP2D6-PM group. Common substrates metabolized by CYPD26 are tricyclic antidepressants, many SSRIs, venlafaxine, and antipsychotics. Therefore, when presented with any of these drugs, CYP2D6-PM are generally at risk for side effects secondary to the increased bioavailability and prolonged elimination half-lives of these drugs. Theoretically, these patients are also subject to an exaggerated drug response by the same mechanisms. At the other phenotypic extreme, the CYP2D6-UM would be expected to exhibit a poorer therapeutic response to CYP2D6 substrates. Depending on the enzyme affected, this simplified scheme can be used as a basis for preliminary predictions of the effect a particular genotype will have on responsiveness to pharmacologic treatments. However, despite theoretic considerations of using genetic alteration in CYP enzymes, there has thus far been insufficient evidence for clinical applicability of CYP genotyping prior to prescribing either antidepressants (in particular, SSRIs) or antipsychotics for their respective applications.

Role of genetic alteration in treatment response in major depressive disorder

41The response to antidepressants in MDD has been reported to vary as a function of specific genetic alterations in certain candidate genes (comprehensively reviewed by Porcelli et al.). Genes that have an effect on serotonin signaling have been a major focus of study for the pharmacogenomics of depression. The polymorphism in the 5′-promoter region of 5-HTT, 5-HTTLPR, has been shown reliably to influence not only susceptibility for developing MDD, but also response to antidepressant therapy. A number of studies have linked the 5-HTTLPR long (L) allele with greater therapeutic response to SSRIs. Other studies have indicated that the 5-HTTLPR short (S) allele is associated with poorer or slower therapeutic response to SSRIs. However, a number of discordant studies have appeared. In a population of Korean patients, Kim et al. found that the 5-HTTLPR S-allele conferred a greater therapeutic response to SSRIs. Yoshida et al. found this same association in a population of Japanese patients and Lotrich et al. also found this association in older patients. Moreover, a number of studies failed to show any relationship between 5-HTTLPR genotypes and antidepressant response or side effects. Such discrepant findings may be related to particular ethnic or age-specific populations, and these factors should also be considered when evaluating genetic response to antidepressants.

42There is also evidence for a pharmacogenomic role for genetic polymorphisms in the serotonin receptors HTR1A and HTR2A, although there are inconsistencies in these findings as well. Some studies showed an association between the HTR1A rs6295-C/C genotype and increased therapeutic response to SSRIs in Chinese populations but Kato et al. found the alternate genotype, rs6295-G/G, to be associated with increased response to SSRIs. However, other groups have been unsuccessful in identifying a relationship between SSRIs and polymorphisms in HTR1A. The data for HTR2A presents similarly, with many authors observing that particular genetic alterations, including the rs6311-G allele, the rs9316233-G allele, rs2224721, rs1923884, rs7997012, rs6313, rs799701, rs3125, rs1923882, and rs6314, are associated with increased response to SSRIs. Murphy et al. compared the SSRI paroxetine with the tetracyclic antidepressant mirtazapine in an 8-week double-blind randomized control trial, to identify potential genetic predictors of efficacy and side effects. This group characterized variation in HTR2A in 246 older patients with MDD undergoing the trial, and found that discontinuing use of paroxetine was significantly associated with the HTR2A rs6313-C allele in a dose-dependent manner. Moreover, carriers of the HTR2A rs6313-C/C genotype experienced more severe side effects than did those with the other genotypes. Notably, there was no significant influence of the HTR2A rs6313 genotypes on mirtazapine side effects. Such findings stand in contrast with other groups, who did not observe an effect of HTR2A variation on antidepressant response.

43Because HPA axis disruption has been associated with MDD susceptibility and pathogenesis, genetic targets within the HPA axis represent plausible candidates for differential antidepressant response. Notably, polymorphisms in the FKBP5 gene have been associated both with increasing susceptibility to MDD (whose conferred susceptibility is further attenuated by environmental stress) and with differential response to antidepressant therapy. In fact, Binder et al. characterized a significantly faster response to SSRIs, TCAs, and mirtazapine in patients with MDD who were homozygous (TT) for the FKBP5 marker rs1360780 compared with the heterozygotes (TC) and homozygote major allele carriers (CC) combined. In a pharmacogenetic association study of genetic variants in CRHBP and response to citalopram, Binder and colleagues identified a SNP significantly associated with both remission and reduction of depressive symptoms in Hispanic and African-American outpatients with MDD.

44Finally, the endogenous opioid system has been implicated in MDD, making the μ-opioid receptor, OPRM1, an attractive target for evaluation of antidepressant response variance secondary to genetic variance. Garricock et al. genotyped 53 separate SNPs in the OPRM1 gene in 1,631 STAR*D samples, and found significant associations for polymorphic variation in OPRM1 and citalopram response and remission. Moreover, the association between the commonly studied SNP rs1799971 and citalopram treatment outcome provided some evidence that this effect is influenced by ancestry groups. The authors expressed some caution in the interpretation of the findings, because even with the use of the same samples, none of the OPRM1 variants met genome-wide significance, and the associations identified could reflect a placebo effect.

45Of note, there are four published GWAS for SSRI antidepressant response, three of which stem from assessment of the samples involved in the STAR*D study and one from the Genome-Based Therapeutic Drugs for Depression (GENDEP). Despite the number of GWAS, only one marker in the Papilin (PAPLN) gene had a sufficiently robust association with antidepressant response (to suicidal ideation) to survive correction for multiple testing. This highlights a benefit of the GWAS approach to pharmacogenomic inquiries; based on a candidate gene approach, PAPLN, which encodes a proteoglycan-sulfated glycoprotein, would probably have been overlooked. However, the paucity of significant findings also emphasizes the likely multifactorial nature of antidepressant response, not easily uncovered with current GWAS designs.

Role of genetic alteration in treatment response in bipolar disorder

46Similar to antidepressant response in MDD, numerous candidate genes have been evaluated for the effect of their genetic variation on BD therapy, most of which have focused on lithium. Lithium response to variation in candidate genes has some notable associations including 5-HTTLPR, CLOCK, BDNF, X-box binding protein 1 (XBP1), glycogen-synthase kinase 3 beta (GSK3B), breakpoint cluster region (BCR), cAMP responsive element binding proteins 1to 3 (CREB 1, 2, and 3) and neurotrophic tyrosine kinase receptor, type 2 (NTRK2).

Role of genetic alteration in treatment response in schizophrenia

47Numerous studies have begun to pinpoint associations between genetic variants in some individuals with SZ and the tolerability and therapeutic efficacy of antipsychotic medications. Tardive dyskinesia (TD) is an often debilitating motor disorder characterized by hyperkinetic, repetitive, and involuntary movements, which is experienced by approximately 30% of individuals with chronic SZ on long-term antipsychotic treatment (usually with first-generation antipsychotics). There are several studies providing evidence for genetic variation affecting susceptibility to TD in response to antipsychotic treatment. For example, polymorphisms near the DA receptor D2 gene (Taq1A, minor allele, rs1800497) and in the DA receptor D3 gene (DRD3-Ser9Gly, rs6280) have been linked with protection against TD and increased susceptibility for developing TD, respectively. However, Woo and colleagues were unable to find any association between the DRD3 Ser9Gly in their study of 113 Korean patients with SZ. Moreover, data analysis from the NIMH Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE), a double-blind study that compared the first-generation antipsychotic perphenazine with four second-generation antipsychotics, did not find evidence for association with TD for either polymorphism. Other genetic variations positively associated with TD have been identified in the genes for the COMT catecholamine-degrading enzyme (Met158Val, Val allele), the manganese isoform of superoxide dismutase (MnSOD), a mitochondrial enzyme involved in oxidative metabolism (homozygote Ala genotype at rs4880, MnSOD-Ala9Val, with a protective effect for Val carriers) and the serotonergic receptor gene 5-HT2A (C allele at promoter region T102C, rs6313 in older patients). However, conflicting reports have also been published for the MnSOD and 5-HT2A variants.

48First-generation antipsychotics are associated with a risk for TD, whereas several of the second-generation antipsychotics (and first-generation antipsychotic, chlorpromazine) can increase the risk for the metabolic syndrome and or isolated weight gain in nearly one-third of patients with SZ. Studies of association of genetic variation with these side effects include associations with polymorphisms in the gene for the serotonin receptor subtype 2C (HTR2C) and in the gene for leptin (LEP), which is important for satiety and adipose regulation. These association studies have reported positive associations with metabolic syndrome (HTR2C intragenic polymorphism rs1414334-C for risperidone and clozapine), less weight gain with HT2RC SNPs (HTR2C −759 C→T and −697 G→C promoter polymorphisms, rs3813929-T and rs518147-C, respectively), and increased weight gain with the LEP promoter SNP −2548 A→G (G allele) (). However, contradictory findings have also been published. Furthermore, Opgen-Rhein et al. were unable to replicate the LEP association with increased weight gain.

49Agranulocytosis, or severe reduction in a particular class of white blood cells, is a serious side effect occurring in approximately 1% of individuals receiving treatment with the atypical antipsychotic clozapine. This property limits clozapine’s clinical use despite its clear therapeutic efficacy in refractory patients. Evidence for genetic variants conferring resistance or increasing susceptibility to clozapine-induced agranulocytosis (CIA) is reflected in a number of studies, although the relatively low incidence of CIA has limited study sizes and effective replication studies. The human leukocyte antigen (HLA) system is comprised of a host of genes that are important in immune system modulation, and it has thus far produced the most promising genetic associations with CIA. These associations include several genetic variants involving the HLA-DQB1 locus, and have become incorporated into a commercially available test, although the clinical usefulness of this test has not been established, owing to its low sensitivity. Additionally, a small GWAS provides preliminary confirmation of the HLA-CIA association.

50In a double-blind study, the NIMH CATIE compared the first-generation antipsychotic perphenazine with four second-generation antipsychotics: olanzapine, risperidone, quetiapine, and ziprasidone. The CATIE trial is a rich resource explored by researchers interested in determining why there were differential responses to antipsychotics. A 2009 analysis of data from the CATIE study was unable to find any significant association (following correction for multiple testing) between 2,769 potential SNPs and 21 pharmacogenetic phenotypes. A GWAS, also drawing from CATIE data, analyzed 738 subjects with SZ for association between SNPs and antipsychotic response, and identified one significant locus at rs17390445 associated with improved SZ-positive symptoms to ziprasidone treatment, although the specific biological relevance of the locus is unclear.

51Studies of the gene encoding a voltage-gated potassium channel, subtype H (KCNH2), have generated some discussion about the possibility of detecting likely responders to atypical antipsychotic therapy. Previous reports of SZ-KCNH2 SNP associations, along with knowledge that antipsychotics bind to KCNH2-encoded channels, fueled inquiry of how risk alleles in KCNH2 might predict treatment response in SZ. Apud et al. analyzed data on the relationship between various KCNH2 genotypes and atypical antipsychotic treatment response from two sources: the 364 patients of the CATIE study and an NIMH cohort of 54 partially treatment-resistant patients with SZ enrolled in a double-blind, placebo-controlled, crossover study (antipsychotics included olanzapine, quetiapine, risperidone, ziprasidone, and aripiprazole). The authors found that individuals with a TT genotype for rs1036145 (T allele previously established as an SZ-risk allele) exhibited significantly greater symptom improvement than those with either the TC or CC-genotypes (P = 0.0395). Specifically, two groups of patients homozygous for rs1036145-TT from the NIMH cohort (those receiving placebo first and those receiving active drug first), showed greater change in positive symptom ratings on the Positive and Negative Syndrome Scale (PANSS) compared with their heterozygote and CC-genotype counterparts. Similarly, in the larger CATIE group, patients with the rs1036145-TT or rs3800779-TT genotypes also showed greater improvement in positive symptoms and general psychopathology than their counterparts (rs1036145-TC/CC or rs3800779-TC/CC, respectively). Furthermore, patients carrying the rs1036145-TT homozygous genotype were far more likely to remain on their medication than the homozygous non-risk genotype (rs1036145-CC) (hazard ratio = 0.208,P = 0.033). The similar relationships of atypical antipsychotic treatment response with KCNH2 genotypes in two separate trials is encouraging evidence that genotyping may help guide therapeutic decisions in SZ.

52Finally, meta-analyses on the DA D2 and D3 receptor polymorphisms have been conducted, seeking association with therapeutic response to antipsychotics. Zhang et al.carried out a meta-analysis of 10 studies to determine the relationship between the DRD2 polymorphisms, Taq1A and –141C Ins/Del, and antipsychotic response. They were unable to detect any relationship between clinical response and the Taq1A polymorphism A1/A1 genotype and A1 carriers compared with A2/A2 genotype (pooled OR = 1.39, 95% CI 0.91 to 2.13, P = 0.13 and pooled OR = 1.30, 95% CI 0.92 to 1.84, P = 0.14, respectively), despite previous association findings of clinical response to haloperidol in acute psychosis, risperidone in first-episode antipsychotic-naïve patients with SZ, and aripiprazole in patients with acutely exacerbated SZ. They did report a significant relationship between the -141C Del carriers compared with patients with the 141C Ins/Ins genotype: -141C Del carriers tended to have poorer therapeutic response to antipsychotics compared with 141C Ins/Ins carriers (pooled OR = 0.65, 95% CI 0.43 to 0.97, P = 0.03). Results for association of the DRD3 polymorphism, Ser9Gly, with antipsychotic treatment response have been equivocal. An initial meta-analyses conducted by Jönsson et al. found that people with the DRD3 Ser9 allele, the Ser/Ser and Ser/Gly genotypes were more likely to respond to typical antipsychotics, and less likely to respond to clozapine compared with their counterparts. However, a more recent meta-analysis by Hwang et al. was unable to identify any significant association between the Ser9Gly polymorphism and antipsychotic drug response after increasing the sample size from 233 to 758 by including original analyses and studies published after the Jönsson meta-analysis.

Emerging applications

53The types of applications that will greatly affect the prospect of personalized medicine in psychiatry will involve continued improvements in genomic inquiries and continued development of genomic testing protocols. Apart from increasing efficiency in genomic techniques, expanding the substrate types for study to include transcriptomics and proteomics (the study of all expressed messenger RNA (mRNA) and all proteins, respectively), will exponentially improve the knowledge base and ability to make informed decisions in personalizing psychiatry. Furthermore, studies that take a multidisciplinary approach, combining the categories (for example, gene × environment interactions or endophenotypes × environmental interactions.) that generate unique phenotypic expression of illness will provide new perspectives and will increase the database from which to draw further studies. Moreover, development of tools to manage and integrate this information and the development of pharmacogenomic tests for use in clinical practice will be greatly beneficial in generating clinically relevant decision trees for use in personalized psychiatry. For example, targeting the molecules responsible for epigenetic regulation may prove to be a promising means of modifying outcomes in psychiatric illnesses. In addition, studies that relate genetics not only to pharmacologic therapy, but to other psychotherapeutics, including various psychotherapies (such as cognitive behavioral therapy and dialectical behavioral therapy), light therapy, deep-brain stimulation, electroconvulsive therapy, and transcranial magnetic stimulation (TMS), will serve to further refine and optimize psychiatric care. Finally, the importance of developing neuroimaging methods and their application to psychiatry will continue to have significant effects on personalizing psychiatry, and this is discussed in greater detail below.

Imaging genetics in psychiatry

54A rapidly advancing area likely to have a major influence on personalized medicine in psychiatry is neuroimaging, and more specifically, neuroimaging genomics. Briefly, imaging genetics uses imaging measures as quantitative biological phenotypes. It seeks to incorporate genetics, psychiatry, and neuroscience in a way that relates genetic variation with protein function, brain structure and connectivity, and psychopathology. Neuroimaging genetics allows conduction of experiments that relate genetic change to outcomes of measurable, repeatable tests of brain structure or function. Two major neuroimaging genetic approaches are 1) identification of imaging alterations in a population with a well-defined genetically determined illness; and/or 2) verification of the effects of specific genetic changes. A particularly useful aspect of defining biological phenotypes using imaging is the distancing of disease from subjective self-report and inconsistent diagnostics. Furthermore, the ability to study in vivo change and change over time in psychiatric illness is paramount given the neuronal plasticity (or lack thereof) already identified in various psychopathologies. In essence, neuroimaging genetics has the potential to lead to better comprehension of the pathophysiology of common psychiatric disorders by evaluating the relationship between imaging phenotypes and genetic variation. Once interventions such as antidepressant therapy or TMS treatment (discussed below) are introduced into the equation, conclusions drawn from correlations may give rise to an understanding of causation. Explorations of concurrent intervention with real-time imaging, such as the assessment of self-regulation of frontal cortical activation (using neurofeedback) in nicotine dependence and craving, coupled with real-time fMRI, have led to this technology and its applications expanding in exciting new directions. For example, trials using this type of volitional reduction with neurofeedback in the treatment of MDD are under way, building upon previous works by the same group (; I. Gotlib, personal communication, 2012). One group is conducting additional trials in PTSD using concurrent TMS-EEG (technique as described by Johnson et al.), which employs active therapeutic intervention with concurrent imaging (A. Etkin, personal communication, 2012) and is probably informed by the group member’s previous characterization of anxiety using fMRI.

55Furthermore, there already exist a number of examples of imaging genetics with psychiatric implications. We describe several examples that epitomize the types of studies and progress being made in imaging genetics (additional notable findings relevant to genes discussed throughout the review can be found in Table 1). Prominent examples are seen with in MDD, with the association between smaller hippocampal volumes and polymorphisms within the 5-HTTLPR region, and with the BDNF Val66Met polymorphism. However, there are some limitations to this field. Neuroimaging genetics is a relatively new area, subject to initial missteps, including false positives and imprecise interpretations. There is skepticism that functional neuroimaging studies (for example, those involving fMRI) actually show the functional change being queried. The output measure of fMRI is blood oxygen level dependent (BOLD) change, which is thought to reflect neuronal activation. Of note, there is a significant lag between the supposed measured neuronal activity and fMRI change due to the cardiovascular changes necessary to increase BOLD in response to neuronal activation. Various imaging methods, each with their own strengths and weaknesses, have the potential to contribute to clarification of this process, often in complementary ways. For example, where there is some temporal disconnection between neuronal activation and BOLD response, diffusion tensor imaging (DTI), which is sensitive to directional diffusion of water along neural pathways, exhibits a more proximate relationship to neuronal activation. MR spectroscopy (MRS) can provide chemical profiles capable of differentiating between brain pathologies. Although the use of positron emission tomography/single-photon emission computed tomography (PET/SPECT) is more invasive than the other methods described, it has the advantage of allowing in vivo monitoring of molecular changes such as receptor or transporter binding density in response to therapy (a summary of select imaging findings is given in Table 1).

Conclusion

56In this review, we have focused on the components and tools that are proving to be instrumental in personalizing medicine in psychiatry. We have discussed the types of information that can be garnered and eventually used in tailoring psychiatric therapies to the individual. This information can be found in the form of particular genetic and epigenetic changes more characteristic in the psychiatrically ill or in observable biomarkers that are reflective of illness. Additionally, environmental influences are evaluated; in particular, how their interaction with genetic variation can lead to disease attenuation or exacerbation. Furthermore, we have discussed how the definition of the illnesses can influence the tailoring of individualized therapies. For example, many psychiatric disorders show phenotypic heterogeneity at the same time as having symptoms that overlap with other psychiatric illnesses that may presumably share some fundamental biologic underpinnings. Indeed, uncovering the biological basis of individual symptoms may prove to be as or more helpful in understanding the pathophysiology of the illness than forcing a constellation of co-occurring symptoms to fit together under one biologically plausible explanation. What we will probably experience is a refining of the diagnostic process; in some cases, recognizing spectrums of disease and in others, homing in on specific biological features of an illness.

57It should be noted that these categories for defining an individual’s unique psychiatric phenotype are artificially separated to facilitate a conceptual framework, and there is substantial overlap between each category (Table 2). For example, an illustration of how genetic variation interacts with environmental factors is apparent in CRHR1 polymorphism haplotypes, which are not only associated with MDD but also interact synergistically with childhood trauma to increase the risk of MDD. Another example is the dexamethasone-binding capacity of leukocytes; although this is not used in the diagnosis of PTSD, it can be used as a biomarker or a proxy measure for glucocorticoid receptor number. In turn, this measurement might help screen persons likely to develop PTSD, because greater glucocorticoid receptor density is predictive of risk for PTSD symptoms in military personnel returning from deployment.

58We also discussed the use of pharmacogenomics in psychiatry. The best-studied pharmacogenomics in psychiatry are the CYP450 liver enzymes, responsible for the metabolism of many psychotropic drugs. Various polymorphisms in these enzymes predispose an individual to enhanced or poorer therapeutic and/or side-effect response to certain medications. Despite robust findings of association with the particular CYP450 genotypes and altered response to psychotropics, there remains insufficient evidence to support CYP450 genotype screening. Additionally, many of the genetic alterations described in this review also are relevant to pharmacogenomic paradigms. Examples include the poor response to SSRIs seen in Caucasian women with MDD who are carriers of the 5-HTTLPR short allele, or the faster response to SSRIs seen in patients with MDD who are homozygous T for the FKBP5 marker rs1360780. Naturally, there is still work to be done in psychiatric pharmacogenomics, as causative treatment strategies for these disorders have yet to be implemented.

59The prospect of personalized medicine in psychiatry more or less reflects ideals still largely unrealized. Currently, the field is at the information-gathering infancy stage. The greatest progress can be expected at the intersections of the categories described above, such as gene × environment and genes × biomarkers, which will poise psychiatry to make biological system-based evaluations. Furthermore, some of the emerging applications, including imaging genomics, strengthen our conviction that the future for personalized medicine is highly promising.

Abbreviations

605-HT: 5-hydroxytryptophan (serotonin); 5-HTTLPR: 5-HT transporter-linked polymorphic region; ACC: anterior cingulate cortex; ANK3: ankyrin 3; APOE: apolipoprotein E; ARNTL: aryl hydrocarbon receptor nuclear translocator-like BmaL1; BCR: breakpoint cluster region; BD: bipolar disorder; BDNF: brain-derived neurotrophic factor; BOLD: blood oxygen level dependent; CACNA1C: calcium channel, voltage-dependent, L type alpha 1C subunit; CATIE: Clinical Antipsychotic Trials of Intervention Effectiveness; Cho: choline; CIA: clozapine-induced agranulocytosis; CLOCK: circadian locomotor output cycles kaput protein; CNS: central nervous system; COMT: catechol-O-methyltransferase; CpG: cytosine-phosphate-guanine; CREB: cAMP responsive element binding proteins 1 to 3; CRF: corticotropin-releasing factor; CRH: corticotropin-releasing hormone; CRHBP: corticotropin-releasing hormone-binding protein; CRHR1: corticotropin-releasing hormone, receptor 1; CRY1/CRY2: cryptochrome 1 and 2; CSF: cerebrospinal fluid; CT: computed tomography; CYP: cytochrome P450; DA: dopamine; DAO: D-amino acid oxidase; DEX/CRH: dexamethasone/corticotropin-releasing hormone; DISC1: disrupted in schizophrenia, 1; dlPFC: dorsolateral pre-frontal cortex; DME: drug-metabolizing enzymes; DMNT: DNA methyltransferase; DRD1/2/4: dopamine receptor, D1/D2/D4; DTI: diffusion tensor imaging; DTNBP1: dystobrevin binding protein 1; ECT: electroconvulsive therapy; EM: extensive metabolizers; FKBP5: FK506-binding protein; fMRI: functional magnetic resonance imaging; GABA: gamma-aminobutyric acid; GABRB2: GABA A receptor, beta 2; GENDEP: Genome-Based Therapeutic Drugs for Depression; GHQ: General Health Questionnaire; GRIN2B: glutamate receptor, ionotrophic, N-methyl D-aspartate 2B; GWAS: genome-wide association studies; 1H-MRS: positron magnetic resonance spectroscopy; ISC: International Schizophrenia Consortium; HDAC1: histone deacetylase 1; HDACi: HDAC inhibitors; HLA: human leukocyte antigen; HP: haptoglobin; HPA: hypothalamic-pituitary-adrenal; HPC: hippocampus; HTR2A and HRT2C: 5-hydroxytryptamine (serotonin) receptor 2A and 2C, G-protein coupled; IL-1B: interleukin 1 beta; KCNH2: potassium voltage-gated channel, subfamily H; IM: intermediate metabolizers; ISC: International Schizophrenia Consortium; LEP: leptin; LD: linkage disequilibrium; LG: licking and grooming; LINC: links the nucleoskeleton to the cytoskeleton; MAOA: monoamine oxidase A; MB: membrane-bound; MCM: mood-congruent memory; MDD: major depressive disorder; MGS: Molecular Genetics of Schizophrenia; MHC: major histocompatibility complex; MHPG: 3-methoxy-4-hydroxphenylglycol; miRNA: microRNA; MnSOD: manganese isoform of superoxide dismutase; MRI: magnetic resonance imaging; MRS: mRNA, messenger RNA; MRS: magnetic resonance spectroscopy; MTHFR: methylenetetrahydrofolate reductase (NAD(P)H); NAA: N-acetylaspartate; NCAN: neurocan; ND: never-depressed; NIMH: National Institute of Mental Health; NIMH-ECA: National Institute of Mental Health Catchment Area; NMDA: N-methyl-D-aspartate; NR2B: NMDA receptor subunit 2B; NR3C1: neuron-specific glucocorticoid receptor; NRG1: neuregulin 1; ODZ4: odd Oz/ten-m homolog 4; PANSS: Positive and Negative Syndrome Scale; PAPLN: papilin; PER1/PER2/PER3: period 1/2/3; PET: positron emission tomography; PFC: pre-frontal cortex; PLXNA2: plexin A2; SLC6A4: dopamine transporter gene A4; PM: poor metabolizers; PTSD: post-traumatic stress disorder; RD: remitted-depressed; SGENE: Schizophrenia Genetics Consortium; sib-tbt: Sibling-Transmission Disequilibrium Test; SNP: single-nucleotide polymorphism; SSL: schizophrenia susceptibility locus; SSRI: Selective serotonin reuptake inhibitor; STAR*D: Sequenced Treatment Alternatives to Relieve Depression; SYNE: spectrin repeat containing, nuclear envelope; SZ: Schizophrenia; SPECT: single-photon emission computed tomography; TP53: tumor protein p53; TPH 1/2: tryptophan hydroxylase 1/2; TD: tardive dyskinesia; TORDIA: Treatment of SSRI-Resistant Depression in Adolescents; TMS: transcranial magnetic stimulation; UM: ultra-rapid metabolizers; vlPFC: ventrolateral pre-frontal cortex; VNTR: variable number tandem repeat regions; XBP1: X-box binding protein 1; ZNF804A: zinc finger 804A.

Competing interests

61The authors declare that they have no competing interests.

Authors’ contributions

62UO wrote the first draft of the manuscript; UO, CW, and CN made substantial contributions to conception and design of the review, reviewed and revised the first and subsequent drafts for intellectual content. All authors have read and approved the final manuscript.

Pre-publication history

63The pre-publication history for this paper can be accessed here:

64http://www.biomedcentral.com/1741-7015/11/132/prepub

References 381

1.
Myers AJ Nemeroff CB New Vistas in the Management of Treatment-Refractory Psychiatric Disorders: Genomics and Personalized MedicineFocus2010 8525535
Not in our library
2.
Mehta R Jain RK Badve S Personalized medicine: the road aheadClin Breast Cancer2011 112026
Not in our library10.3816/cbc.2011.n.004
3.
Conneally PM Huntington disease: genetics and epidemiologyAm J Hum Genet1984 36506526
Not in our library
4.
Kessler RC McGonagle KA Zhao S Nelson CB Hughes M Eshleman S Wittchen HU Kendler KS Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity SurveyArch Gen Psychiatry1994 51819
Not in our library10.1001/archpsyc.1994.03950010008002
5.
Risch SC Nemeroff CB Neurochemical alterations of serotonergic neuronal systems in depressionJ Clin Psychiatry1992 5337
Not in our library
6.
Krishnan V Nestler EJ The molecular neurobiology of depressionNature2008 455894902
Not in our library10.1038/nature07455
7.
Ogilvie AD Battersby S Bubb VJ Fink G Harmar AJ Goodwim GM Smith CA Polymorphism in serotonin transporter gene associated with susceptibility to major depressionLancet1996 347731733
Not in our library10.1016/s0140-6736(96)90079-3
8.
Hoefgen B Schulze TG Ohlraun S Von Widdern O Höfels S Gross M Heidmann V Kovalenko S Eckermann A Kölsch H Metten M Zobel A Becker T Nöthen MM Propping P Heun R Maier W Rietschel M The power of sample size and homogenous sampling: association between the 5-HTTLPR serotonin transporter polymorphism and major depressive disorderBiol Psychiatry2005 57247251
Not in our library10.1016/j.biopsych.2004.11.027
9.
Gao J Pan Z Jiao Z Li F Zhao G Wei Q Pan F Evangelou E TPH2 Gene Polymorphisms and Major Depression - A Meta-AnalysisPLoS One2012 7e36721
Not in our library10.1371/journal.pone.0036721
10.
Walther DJ Bader M A unique central tryptophan hydroxylase isoformBiochem Pharmacol2003 6616731680
Not in our library10.1016/s0006-2952(03)00556-2
11.
Nash MW Sugden K Huezo-Diaz P Williamson R Sterne A Purcell S Sham PC Craig IW Association analysis of monoamine genes with measures of depression and anxiety in a selected community sample of siblingsAm J Med Genet B Neuropsychiatr Genet2005 135B3337
Not in our library10.1002/ajmg.b.30063
12.
Gizatullin R Zaboli G Jönsson EG Asberg M Leopardi R Haplotype analysis reveals tryptophan hydroxylase (TPH) 1 gene variants associated with major depressionBiol Psychiatry2006 59295300
Not in our library10.1016/j.biopsych.2005.07.034
13.
Zill P Baghai TC Zwanzger P Schüle C Eser D Rupprecht R Möller H-J Bondy B Ackenheil M SNP and haplotype analysis of a novel tryptophan hydroxylase isoform (TPH2) gene provide evidence for association with major depressionMol Psychiatry2004 910301036
Not in our library10.1038/sj.mp.4001525
14.
Zhang X Beaulieu J-M Sotnikova TD Gainetdinov RR Caron MG Tryptophan hydroxylase-2 controls brain serotonin synthesisScience2004 305217
Not in our library10.1126/science.1097540
15.
Zhang X Gainetdinov RR Beaulieu J-M Sotnikova TD Burch LH Williams RB Schwartz DA Krishnan KRR Caron MG Loss-of-function mutation in tryptophan hydroxylase-2 identified in unipolar major depressionNeuron2005 451116
Not in our library10.1016/j.neuron.2004.12.014
16.
Garriock HA Allen JJB Delgado P Nahaz Z Kling MA Carpenter L Burke M Burke W Schwartz T Marangell LB Husain M Erickson RP Moreno FA Lack of association of TPH2 exon XI polymorphisms with major depression and treatment resistanceMol Psychiatry2005 10976977
Not in our library10.1038/sj.mp.4001712
17.
Serretti A Chiesa A Porcelli S Han C Patkar AA Lee S-J Park MH Pae C-U Influence of TPH2 variants on diagnosis and response to treatment in patients with major depression, bipolar disorder and schizophreniaPsychiatry Res2011 1892632
Not in our library10.1016/j.psychres.2011.02.001
18.
Schuhmacher A Becker T Rujescu D Quednow BB Lennertz L Wagner M Benninghoff J Rietschel M Häfner H Franke P Wölwer W Gaebel W Maier W Mössner R Investigation of tryptophan hydroxylase 2 (TPH2) in schizophrenia and in the response to antipsychoticsJ Psychiatric Res2012 4610731080
Not in our library10.1016/j.jpsychires.2012.04.021
19.
Zhang C Li Z Shao Y Xie B Du Y Fang Y Yu S Association study of tryptophan hydroxylase-2 gene in schizophrenia and its clinical features in Chinese Han populationJ Mol Neurosci2011 43406411
Not in our library10.1007/s12031-010-9458-2
20.
Kim Y-K Lee H-J Yang J-C Hwang J-A Yoon H-K A tryptophan hydroxylase 2 gene polymorphism is associated with panic disorderBehav Genet2009 39170175
Not in our library10.1007/s10519-008-9254-8
21.
Mössner R Walitza S Geller F Scherag A Gutknecht L Jacob C Bogusch L Remschmidt H Simons M Herpertz-Dahlmann B Fleischhaker C Schulz E Warnke A Hinney A Wewetzer C Lesch K-P Transmission disequilibrium of polymorphic variants in the tryptophan hydroxylase-2 gene in children and adolescents with obsessive-compulsive disorderInt J Neuropsychopharmacol2006 9437442
Not in our library10.1017/s1461145705005997
22.
Walitza S Renner TJ Dempfle A Konrad K Wewetzer C Halbach A Herpertz-Dahlmann B Remschmidt H Smidt J Linder M Flierl L Knölker U Friedel S Schäfer H Gross C Hebebrand J Warnke A Lesch KP Transmission disequilibrium of polymorphic variants in the tryptophan hydroxylase-2 gene in attention-deficit/hyperactivity disorderMol Psychiatry2005 1011261132
Not in our library10.1038/sj.mp.4001734
23.
Nemeroff CB Clinical significance of psychoneuroendocrinology in psychiatry: focus on the thyroid and adrenalJ Clin Psychiatry1989 501320discussion 21–22
Not in our library
24.
Binder EB Salyakina D Lichtner P Wochnik GM Ising M Pütz B Papiol S Seaman S Lucae S Kohli MA Nickel T Künzel HE Fuchs B Majer M Pfennig A Kern N Brunner J Modell S Baghai T Deiml T Zill P Bondy B Rupprecht R Messer T Köhnlein O Dabitz H Brückl T Müller N Pfister H Lieb R Polymorphisms in FKBP5 are associated with increased recurrence of depressive episodes and rapid response to antidepressant treatmentNat Genet2004 3613191325
Not in our library10.1038/ng1479
25.
Tatro ET Everall IP Masliah E Hult BJ Lucero G Chana G Soontornniyomkij V Achim CL Differential expression of immunophilins FKBP51 and FKBP52 in the frontal cortex of HIV-infected patients with major depressive disorderJ Neuroimmune Pharmacol2009 4218226
Not in our library10.1007/s11481-009-9146-6
26.
Brent D Melhem N Ferrell R Emslie G Wagner KD Ryan N Vitiello B Birmaher B Mayes T Zelazny J Onorato M Devlin B Clarke G DeBar L Keller M Association of FKBP5 polymorphisms with suicidal events in the Treatment of Resistant Depression in Adolescents (TORDIA) studyAm J Psychiatry2010 167190197
Not in our library10.1176/appi.ajp.2009.09040576
27.
Timpl P Spanagel R Sillaber I Kresse A Reul JM Stalla GK Blanquet V Steckler T Holsboer F Wurst W Impaired stress response and reduced anxiety in mice lacking a functional corticotropin-releasing hormone receptor 1Nat Genet1998 19162166
Not in our library10.1038/520
28.
Gillespie CF Binder EB Holtzheimer PE Nemeroff CB Stress and the impact of personalized medicineIntegrative Neuroscience and Personalized Medicine2010 Oxford: Oxford University Press7392
Not in our library
29.
Hartline KM Owens MJ Nemeroff CB Postmortem and cerebrospinal fluid studies of corticotropin-releasing factor in humansAnn N Y Acad Sci1996 78096105
Not in our library10.1111/j.1749-6632.1996.tb15114.x
30.
Arató M Bánki CM Bissette G Nemeroff CB Elevated CSF CRF in suicide victimsBiol Psychiatry1989 25355359
Not in our library10.1016/0006-3223(89)90183-2
31.
Nemeroff CB Widerlöv E Bissette G Walléus H Karlsson I Eklund K Kilts CD Loosen PT Vale W Elevated concentrations of CSF corticotropin-releasing factor-like immunoreactivity in depressed patientsScience1984 22613421344
Not in our library10.1126/science.6334362
32.
Liu Z Zhu F Wang G Xiao Z Wang H Tang J Wang X Qiu D Liu W Cao Z Li W Association of corticotropin-releasing hormone receptor1 gene SNP and haplotype with major depressionNeurosci Lett2006 404358362
Not in our library10.1016/j.neulet.2006.06.016
33.
Papiol S Arias B Gastó C Gutiérrez B Catalán R Fañanás L Genetic variability at HPA axis in major depression and clinical response to antidepressant treatmentJ Affect Disord2007 1048390
Not in our library10.1016/j.jad.2007.02.017
34.
Lekman M Laje G Charney D Rush AJ Wilson AF Sorant AJM Lipsky R Wisniewski SR Manji H McMahon FJ Paddock S The FKBP5-gene in depression and treatment response–an association study in the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) CohortBiol Psychiatry2008 6311031110
Not in our library10.1016/j.biopsych.2007.10.026
35.
Claes S Villafuerte S Forsgren T Sluijs S Del-Favero J Adolfsson R Van Broeckhoven C The corticotropin-releasing hormone binding protein is associated with major depression in a population from Northern SwedenBiol Psychiatry2003 54867872
Not in our library10.1016/s0006-3223(03)00425-6
36.
Van Den Eede F Venken T Del-Favero J Norrback K-F Souery D Nilsson LG Van den Bossche B Hulstijn W Sabbe BGC Cosyns P Mendlewicz J Adolfsson R Van Broeckhoven C Claes SJ Single nucleotide polymorphism analysis of corticotropin-releasing factor-binding protein gene in recurrent major depressive disorderPsychiatry Res2007 1531725
Not in our library10.1016/j.psychres.2006.12.018
37.
Smoller JW Finn CT Family, twin, and adoption studies of bipolar disorderAm J Med Genet C Semin Med Genet2003 123C4858
Not in our library10.1002/ajmg.c.20013
38.
Barnett JH Smoller JW The genetics of bipolar disorderNeuroscience2009 164331343
Not in our library10.1016/j.neuroscience.2009.03.080
39.
Craddock N Sklar P Genetics of bipolar disorder: successful start to a long journeyTrends Genet2009 2599105
Not in our library10.1016/j.tig.2008.12.002
40.
Willour VL Chen H Toolan J Belmonte P Cutler DJ Goes FS Zandi PP Lee RS MacKinnon DF Mondimore FM Schweizer B DePaulo JR Jr Gershon ES McMahon FJ Potash JB Family-based association of FKBP5 in bipolar disorderMol Psychiatry2009 14261268
Not in our library10.1038/sj.mp.4002141
41.
Fallin MD Lasseter VK Avramopoulos D Nicodemus KK Wolyniec PS McGrath JA Steel G Nestadt G Liang K-Y Huganir RL Valle D Pulver AE Bipolar I disorder and schizophrenia: a 440-single-nucleotide polymorphism screen of 64 candidate genes among Ashkenazi Jewish case-parent triosAm J Hum Genet2005 77918936
Not in our library10.1086/497703
42.
Gawlik M Moller-Ehrlich K Mende M Jovnerovski M Jung S Jabs B Knapp M Stoeber G Is FKBP5 a genetic marker of affective psychosis? A case control study and analysis of disease related traitsBMC Psychiatry2006 652
Not in our library10.1186/1471-244x-6-52
43.
Wellcome Trust Case Control ConsortiumGenome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controlsNature2007 447661678
Not in our library10.1038/nature05911
44.
Baum AE Akula N Cabanero M Cardona I Corona W Klemens B Schulze TG Cichon S Rietschel M Nöthen MM Georgi A Schumacher J Schwarz M Abou Jamra R Höfels S Propping P Satagopan J Detera-Wadleigh SD Hardy J McMahon FJ A genome-wide association study implicates diacylglycerol kinase eta (DGKH) and several other genes in the etiology of bipolar disorderMol Psychiatry2008 13197207
Not in our library10.1038/sj.mp.4002012
45.
Benedetti F Serretti A Colombo C Barbini B Lorenzi C Campori E Smeraldi E Influence of CLOCK gene polymorphism on circadian mood fluctuation and illness recurrence in bipolar depressionAm J Med Genet B Neuropsychiatr Genet2003 123B2326
Not in our library10.1002/ajmg.b.20038
46.
Shi J Wittke-Thompson JK Badner JA Hattori E Potash JB Willour VL McMahon FJ Gershon ES Liu C Clock genes may influence bipolar disorder susceptibility and dysfunctional circadian rhythmAm J Med Genet B Neuropsychiatr Genet2008 147B10471055
Not in our library10.1002/ajmg.b.30714
47.
Wager-Smith K Kay SA Circadian rhythm genetics: from flies to mice to humansNat Genet2000 262327
Not in our library10.1038/79134
48.
Mansour HA Wood J Logue T Chowdari KV Dayal M Kupfer DJ Monk TH Devlin B Nimgaonkar VL Association study of eight circadian genes with bipolar I disorder, schizoaffective disorder and schizophreniaGenes Brain Behav2006 5150157
Not in our library10.1111/j.1601-183x.2005.00147.x
49.
Ferreira MAR O’Donovan MC Meng YA Jones IR Ruderfer DM Jones L Fan J Kirov G Perlis RH Green EK Smoller JW Grozeva D Stone J Nikolov I Chambert K Hamshere ML Nimgaonkar VL Moskvina V Thase ME Caesar S Sachs GS Franklin J Gordon-Smith K Ardlie KG Gabriel SB Fraser C Blumenstiel B Defelice M Breen G Gill M Collaborative genome-wide association analysis supports a role for ANK3 and CACNA1C in bipolar disorderNat Genet2008 4010561058
Not in our library10.1038/ng.209
50.
Cichon S Mühleisen TW Degenhardt FA Mattheisen M Miró X Strohmaier J Steffens M Meesters C Herms S Weingarten M Priebe L Haenisch B Alexander M Vollmer J Breuer R Schmäl C Tessmann P Moebus S Wichmann H-E Schreiber S Müller-Myhsok B Lucae S Jamain S Leboyer M Bellivier F Etain B Henry C Kahn J-P Heath S Hamshere M Genome-wide association study identifies genetic variation in neurocan as a susceptibility factor for bipolar disorderAm J Hum Genet2011 88372381
Not in our library10.1016/j.ajhg.2011.01.017
51.
Sklar P Ripke S Scott LJ Large-scale genome-wide association analysis of bipolar disorder identifies a new susceptibility locus near ODZ4Nat Genet2011 43977983
Not in our library10.1038/ng.943
52.
Green EK Grozeva D Forty L Gordon-Smith K Russell E Farmer A Hamshere M Jones IR Jones L McGuffin P Moran JL Purcell S Sklar P Owen MJ O’Donovan MC Craddock N Association at SYNE1 in both bipolar disorder and recurrent major depressionMol Psychiatry2012 18614617
Not in our library10.1038/mp.2012.48
53.
Warren DT Zhang Q Weissberg PL Shanahan CM Nesprins: intracellular scaffolds that maintain cell architecture and coordinate cell function?Expert Rev Mol Med2005 7115
Not in our library10.1017/s1462399405009294
54.
Cardno AG Marshall EJ Coid B Macdonald AM Ribchester TR Davies NJ Venturi P Jones LA Lewis SW Sham PC Gottesman II Farmer AE McGuffin P Reveley AM Murray RM Heritability estimates for psychotic disorders: the Maudsley twin psychosis seriesArch Gen Psychiatry1999 56162168
Not in our library10.1001/archpsyc.56.2.162
55.
Cardno AG Gottesman II Twin studies of schizophrenia: from bow-and-arrow concordances to star wars Mx and functional genomicsAm J Med Genet2000 971217
Not in our library
56.
Gejman PV Sanders AR Kendler KS Genetics of schizophrenia: new findings and challengesAnnu Rev Genomics Hum Genet2011 12121144
Not in our library10.1146/annurev-genom-082410-101459
57.
Purcell SM Wray NR Stone JL Visscher PM O’Donovan MC Sullivan PF Sklar P Common polygenic variation contributes to risk of schizophrenia and bipolar disorderNature2009 460748752
Not in our library10.1038/nature08185
58.
Shi J Levinson DF Duan J Sanders AR Zheng Y Pe’er I Dudbridge F Holmans PA Whittemore AS Mowry BJ Olincy A Amin F Cloninger CR Silverman JM Buccola NG Byerley WF Black DW Crowe RR Oksenberg JR Mirel DB Kendler KS Freedman R Gejman PV Common variants on chromosome 6p22.1 are associated with schizophreniaNature2009 460753757
Not in our library10.1038/nature08192
59.
Stefansson H Ophoff RA Steinberg S Andreassen OA Cichon S Rujescu D Werge T Pietiläinen OPH Mors O Mortensen PB Sigurdsson E Gustafsson O Nyegaard M Tuulio-Henriksson A Ingason A Hansen T Suvisaari J Lonnqvist J Paunio T Børglum AD Hartmann A Fink-Jensen A Nordentoft M Hougaard D Norgaard-Pedersen B Böttcher Y Olesen J Breuer R Möller H-J Giegling I Common variants conferring risk of schizophreniaNature2009 460744747
Not in our library10.1038/nature08186
60.
O’Donovan MC Craddock N Norton N Williams H Peirce T Moskvina V Nikolov I Hamshere M Carroll L Georgieva L Dwyer S Holmans P Marchini JL Spencer CCA Howie B Leung H-T Hartmann AM Möller H-J Morris DW Shi Y Feng G Hoffmann P Propping P Vasilescu C Maier W Rietschel M Zammit S Schumacher J Quinn EM Schulze TG Williams NM Giegling I Iwata N Ikeda M Darvasi A Shifman S He L Duan J Sanders AR Levinson DF Gejman PV Cichon S Nöthen MM Gill M Corvin A Rujescu D Kirov G Owen MJ Buccola NG Mowry BJ Freedman R Amin F Black DW Silverman JM Byerley WF Cloninger CR Identification of loci associated with schizophrenia by genome-wide association and follow-upNat Genet2008 4010531055
Not in our library10.1038/ng.201
61.
Riley B Thiselton D Maher BS Bigdeli T Wormley B McMichael GO Fanous AH Vladimirov V O’Neill FA Walsh D Kendler KS Replication of association between schizophrenia and ZNF804A in the Irish Case–control Study of Schizophrenia sampleMol Psychiatry2010 152937
Not in our library10.1038/mp.2009.109
62.
Steinberg S Mors O Børglum AD Gustafsson O Werge T Mortensen PB Andreassen OA Sigurdsson E Thorgeirsson TE Böttcher Y Olason P Ophoff RA Cichon S Gudjonsdottir IH Pietiläinen OPH Nyegaard M Tuulio-Henriksson A Ingason A Hansen T Athanasiu L Suvisaari J Lonnqvist J Paunio T Hartmann A Jürgens G Nordentoft M Hougaard D Norgaard-Pedersen B Breuer R Möller H-J Giegling I Glenthøj B Rasmussen HB Mattheisen M Bitter I Réthelyi JM Sigmundsson T Fossdal R Thorsteinsdottir U Ruggeri M Tosato S Strengman E Kiemeney LA Melle I Djurovic S Abramova L Kaleda V Walshe M Bramon E Vassos E Li T Fraser G Walker N Toulopoulou T Yoon J Freimer NB Cantor RM Murray R Kong A Golimbet V Jönsson EG Terenius L Agartz I Petursson H Nöthen MM Rietschel M Peltonen L Rujescu D Collier DA Stefansson H St Clair D Stefansson K Expanding the range of ZNF804A variants conferring risk of psychosisMol Psychiatry2011 165966
Not in our library10.1038/mp.2009.149
63.
Zhang R Lu SM Qiu C Liu XG Gao CG Guo TW Valenzuela RK Deng HW Ma J Population-based and family-based association studies of ZNF804A locus and schizophreniaMol Psychiatry2011 16360361
Not in our library10.1038/mp.2010.55
64.
Lencz T Morgan TV Athanasiou M Dain B Reed CR Kane JM Kucherlapati R Malhotra AK Converging evidence for a pseudoautosomal cytokine receptor gene locus in schizophreniaMol Psychiatry2007 12572580
Not in our library10.1038/sj.mp.4001983
65.
Williams HJ Norton N Dwyer S Moskvina V Nikolov I Carroll L Georgieva L Williams NM Morris DW Quinn EM Giegling I Ikeda M Wood J Lencz T Hultman C Lichtenstein P Thiselton D Maher BS Malhotra AK Riley B Kendler KS Gill M Sullivan P Sklar P Purcell S Nimgaonkar VL Kirov G Holmans P Corvin A Rujescu D Craddock N Owen MJ O’Donovan MC Fine mapping of ZNF804A and genome-wide significant evidence for its involvement in schizophrenia and bipolar disorderMol Psychiatry2011 16429441
Not in our library10.1038/mp.2010.36
66.
Flora A Garcia JJ Thaller C Zoghbi HY The E-protein Tcf4 interacts with Math1 to regulate differentiation of a specific subset of neuronal progenitorsProc Natl Acad Sci USA2007 1041538215387
Not in our library10.1073/pnas.0707456104
67.
De Pontual L Mathieu Y Golzio C Rio M Malan V Boddaert N Soufflet C Picard C Durandy A Dobbie A Heron D Isidor B Motte J Newburry-Ecob R Pasquier L Tardieu M Viot G Jaubert F Munnich A Colleaux L Vekemans M Etchevers H Lyonnet S Amiel J Mutational, functional, and expression studies of the TCF4 gene in Pitt-Hopkins syndromeHum Mutat2009 30669676
Not in our library10.1002/humu.20935
68.
Pitt D Hopkins I A syndrome of mental retardation, wide mouth and intermittent overbreathingAust Paediatr J1978 14182184
Not in our library10.1111/jpc.1978.14.3.182
69.
Steinberg S De Jong S Andreassen OA Werge T Børglum AD Mors O Mortensen PB Gustafsson O Costas J Pietiläinen OPH Demontis D Papiol S Huttenlocher J Mattheisen M Breuer R Vassos E Giegling I Fraser G Walker N Tuulio-Henriksson A Suvisaari J Lönnqvist J Paunio T Agartz I Melle I Djurovic S Strengman E Jürgens G Glenthøj B Terenius L Common variants at VRK2 and TCF4 conferring risk of schizophreniaHum Mol Genet2011 2040764081
Not in our library10.1093/hmg/ddr325
70.
Ripke S Sanders AR Kendler KS Levinson DF Sklar P Holmans PA Lin D Duan J Ophoff RA Andreassen OA Scolnick E Cichon S St Clair D Corvin A Gurling H Werge T Rujescu D Blackwood D Pato CN Malhotra AK Purcell SM Dudbridge F Neale BM Rossin L Visscher PM Posthuma D Ruderfer DM Fanous AH Stefansson H Steinberg S Genome-wide association study identifies five new schizophrenia lociNat Genet2011 43969976
Not in our library10.1038/ng.940
71.
Li T Li Z Chen P Zhao Q Wang T Huang K Li J Li Y Liu J Zeng Z Feng G He L Shi Y Common Variants in Major Histocompatibility Complex Region and TCF4 Gene Are Significantly Associated with Schizophrenia in Han ChineseBiol Psychiatry2010 68671673
Not in our library10.1016/j.biopsych.2010.06.014
72.
Canoll PD Musacchio JM Hardy R Reynolds R Marchionni MA Salzer JL GGF/neuregulin is a neuronal signal that promotes the proliferation and survival and inhibits the differentiation of oligodendrocyte progenitorsNeuron1996 17229243
Not in our library10.1016/s0896-6273(00)80155-5
73.
Anton ES Marchionni MA Lee KF Rakic P Role of GGF/neuregulin signaling in interactions between migrating neurons and radial glia in the developing cerebral cortexDevelopment1997 12435013510
Not in our library10.1242/dev.124.18.3501
74.
Huang YZ Won S Ali DW Wang Q Tanowitz M Du QS Pelkey KA Yang DJ Xiong WC Salter MW Mei L Regulation of neuregulin signaling by PSD-95 interacting with ErbB4 at CNS synapsesNeuron2000 26443455
Not in our library10.1016/s0896-6273(00)81176-9
75.
Liu Y Ford B Mann MA Fischbach GD Neuregulins increase alpha7 nicotinic acetylcholine receptors and enhance excitatory synaptic transmission in GABAergic interneurons of the hippocampusJ Neurosci2001 2156605669
Not in our library10.1523/jneurosci.21-15-05660.2001
76.
Corfas G Roy K Buxbaum JD Neuregulin 1-erbB signaling and the molecular/cellular basis of schizophreniaNat Neurosci2004 7575580
Not in our library10.1038/nn1258
77.
Stefansson H Sigurdsson E Steinthorsdottir V Bjornsdottir S Sigmundsson T Ghosh S Brynjolfsson J Gunnarsdottir S Ivarsson O Chou TT Hjaltason O Birgisdottir B Jonsson H Gudnadottir VG Gudmundsdottir E Bjornsson A Ingvarsson B Ingason A Sigfusson S Hardardottir H Harvey RP Lai D Zhou M Brunner D Mutel V Gonzalo A Lemke G Sainz J Johannesson G Andresson T Gudbjartsson D Manolescu A Frigge ML Gurney ME Kong A Gulcher JR Petursson H Stefansson K Neuregulin 1 and susceptibility to schizophreniaAm J Hum Genet2002 71877892
Not in our library10.1086/342734
78.
Pulver AE Wolyniec PS Housman D Kazazian HH Antonarakis SE Nestadt G Lasseter VK McGrath JA Dombroski B Karayiorgou M Ton C Blouin JL Kempf L The Johns Hopkins University Collaborative Schizophrenia Study: an epidemiologic-genetic approach to test the heterogeneity hypothesis and identify schizophrenia susceptibility genesCold Spring Harb Symp Quant Biol1996 61797814
Not in our library
79.
Kendler KS MacLean CJ O’Neill FA Burke J Murphy B Duke F Shinkwin R Easter SM Webb BT Zhang J Walsh D Straub RE Evidence for a schizophrenia vulnerability locus on chromosome 8p in the Irish Study of High-Density Schizophrenia FamiliesAm J Psychiatry1996 15315341540
Not in our library10.1176/ajp.153.12.1534
80.
Blouin JL Dombroski BA Nath SK Lasseter VK Wolyniec PS Nestadt G Thornquist M Ullrich G McGrath J Kasch L Lamacz M Thomas MG Gehrig C Radhakrishna U Snyder SE Balk KG Neufeld K Swartz KL DeMarchi N Papadimitriou GN Dikeos DG Stefanis CN Chakravarti A Childs B Housman DE Kazazian HH Antonarakis S Pulver AE Schizophrenia susceptibility loci on chromosomes 13q32 and 8p21Nat Genet1998 207073
Not in our library10.1038/1734
81.
Kaufmann CA Suarez B Malaspina D Pepple J Svrakic D Markel PD Meyer J Zambuto CT Schmitt K Matise TC Harkavy Friedman JM Hampe C Lee H Shore D Wynne D Faraone SV Tsuang MT Cloninger CR NIMH Genetics Initiative Millenium Schizophrenia Consortium: linkage analysis of African-American pedigreesAm J Med Genet1998 81282289
Not in our library
82.
Allen NC Bagade S McQueen MB Ioannidis JPA Kavvoura FK Khoury MJ Tanzi RE Bertram L Systematic meta-analyses and field synopsis of genetic association studies in schizophrenia: the SzGene databaseNat Genet2008 40827834
Not in our library10.1038/ng.171
83.
Stefansson H Sarginson J Kong A Yates P Steinthorsdottir V Gudfinnsson E Gunnarsdottir S Walker N Petursson H Crombie C Ingason A Gulcher JR Stefansson K St Clair D Association of neuregulin 1 with schizophrenia confirmed in a Scottish populationAm J Hum Genet2003 728387
Not in our library10.1086/345442
84.
Williams NM Preece A Spurlock G Norton N Williams HJ Zammit S O’Donovan MC Owen MJ Support for genetic variation in neuregulin 1 and susceptibility to schizophreniaMol Psychiatry2003 8485487
Not in our library10.1038/sj.mp.4001348
85.
Benzel I Bansal A Browning BL Galwey NW Maycox PR McGinnis R Smart D St Clair D Yates P Purvis I Interactions among genes in the ErbB-Neuregulin signalling network are associated with increased susceptibility to schizophreniaBehav Brain Funct2007 331
Not in our library10.1186/1744-9081-3-31
86.
Ikeda M Takahashi N Saito S Aleksic B Watanabe Y Nunokawa A Yamanouchi Y Kitajima T Kinoshita Y Kishi T Kawashima K Hashimoto R Ujike H Inada T Someya T Takeda M Ozaki N Iwata N Failure to replicate the association between NRG1 and schizophrenia using Japanese large sampleSchizophr Res2008 10118
Not in our library10.1016/j.schres.2008.01.010
87.
Alaerts M Ceulemans S Forero D Moens LN De Zutter S Heyrman L Lenaerts A-S Norrback K-F De Rijk P Nilsson L-G Goossens D Adolfsson R Del-Favero J Support for NRG1 as a susceptibility factor for schizophrenia in a northern Swedish isolated populationArch Gen Psychiatry2009 66828837
Not in our library10.1001/archgenpsychiatry.2009.82
88.
So H-C Fong PY Chen RYL Hui TCK Ng MYM Cherny SS Mak WWM Cheung EFC Chan RCK Chen EYH Li T Sham PC Identification of neuroglycan C and interacting partners as potential susceptibility genes for schizophrenia in a Southern Chinese populationAm J Med Genet B Neuropsychiatr Genet2010 153B103113
Not in our library10.1002/ajmg.b.30961
89.
Iwata N Suzuki T Ikeda M Kitajima T Yamanouchi Y Inada T Ozaki N No association with the neuregulin 1 haplotype to Japanese schizophreniaMol Psychiatry2004 9126127
Not in our library10.1038/sj.mp.4001456
90.
Vilella E Costas J Sanjuan J Guitart M De Diego Y Carracedo A Martorell L Valero J Labad A De Frutos R Nájera C Moltó MD Toirac I Guillamat R Brunet A Vallès V Pérez L Leon M De Fonseca FR Phillips C Torres M Association of schizophrenia with DTNBP1 but not with DAO, DAOA, NRG1 and RGS4 nor their genetic interactionJ Psychiatr Res2008 42278288
Not in our library10.1016/j.jpsychires.2007.02.005
91.
Jungerius BJ Hoogendoorn MLC Bakker SC Van’t Slot R Bardoel AF Ophoff RA Wijmenga C Kahn RS Sinke RJ An association screen of myelin-related genes implicates the chromosome 22q11 PIK4CA gene in schizophreniaMol Psychiatry2008 1310601068
Not in our library10.1038/sj.mp.4002080
92.
Crowley JJ Keefe RSE Perkins DO Stroup TS Lieberman JA Sullivan PF The neuregulin 1 promoter polymorphism rs6994992 is not associated with chronic schizophrenia or neurocognitionAm J Med Genet B Neuropsychiatr Genet2008 147B12981300
Not in our library10.1002/ajmg.b.30727
93.
Sanders AR Duan J Levinson DF Shi J He D Hou C Burrell GJ Rice JP Nertney DA Olincy A Rozic P Vinogradov S Buccola NG Mowry BJ Freedman R Amin F Black DW Silverman JM Byerley WF Crowe RR Cloninger CR Martinez M Gejman PV No significant association of 14 candidate genes with schizophrenia in a large European ancestry sample: implications for psychiatric geneticsAm J Psychiatry2008 165497506
Not in our library10.1176/appi.ajp.2007.07101573
94.
Jönsson EG Saetre P Vares M Andreou D Larsson K Timm S Rasmussen HB Djurovic S Melle I Andreassen OA Agartz I Werge T Hall H Terenius L DTNBP1, NRG1, DAOA, DAO and GRM3 polymorphisms and schizophrenia: an association studyNeuropsychobiology2009 59142150
Not in our library10.1159/000218076
95.
Yang JZ Si TM Ruan Y Ling YS Han YH Wang XL Zhou M Zhang HY Kong QM Liu C Zhang DR Yu YQ Liu SZ Ju GZ Shu L Ma DL Zhang D Association study of neuregulin 1 gene with schizophreniaMol Psychiatry2003 8706709
Not in our library10.1038/sj.mp.4001377
96.
Zhao X Shi Y Tang J Tang R Yu L Gu N Feng G Zhu S Liu H Xing Y Zhao S Sang H Guan Y St Clair D He L A case control and family based association study of the neuregulin1 gene and schizophreniaJ Med Genet2004 413134
Not in our library10.1136/jmg.2003.014977
97.
Hong C-J Huo S-J Liao D-L Lee K Wu J-Y Tsai S-J Case–control and family-based association studies between the neuregulin 1 (Arg38Gln) polymorphism and schizophreniaNeurosci Lett2004 366158161
Not in our library10.1016/j.neulet.2004.05.027
98.
Li T Stefansson H Gudfinnsson E Cai G Liu X Murray RM Steinthorsdottir V Januel D Gudnadottir VG Petursson H Ingason A Gulcher JR Stefansson K Collier DA Identification of a novel neuregulin 1 at-risk haplotype in Han schizophrenia Chinese patients, but no association with the Icelandic/Scottish risk haplotypeMol Psychiatry2004 9698704
Not in our library10.1038/sj.mp.4001485
99.
Georgieva L Dimitrova A Ivanov D Nikolov I Williams NM Grozeva D Zaharieva I Toncheva D Owen MJ Kirov G O’Donovan MC Support for neuregulin 1 as a susceptibility gene for bipolar disorder and schizophreniaBiol Psychiatry2008 64419427
Not in our library10.1016/j.biopsych.2008.03.025
100.
Hall D Gogos JA Karayiorgou M The contribution of three strong candidate schizophrenia susceptibility genes in demographically distinct populationsGenes Brain Behav2004 3240248
Not in our library10.1111/j.1601-183x.2004.00078.x
101.
Thiselton DL Webb BT Neale BM Ribble RC O’Neill FA Walsh D Riley BP Kendler KS No evidence for linkage or association of neuregulin-1 (NRG1) with disease in the Irish study of high-density schizophrenia families (ISHDSF)Mol Psychiatry2004 9777783image 729
Not in our library10.1038/sj.mp.4001530
102.
Turunen JA Peltonen JO Pietiläinen OPH Hennah W Loukola A Paunio T Silander K Ekelund J Varilo T Partonen T Lönnqvist J Peltonen L The role of DTNBP1, NRG1, and AKT1 in the genetics of schizophrenia in FinlandSchizophr Res2007 912736
Not in our library10.1016/j.schres.2006.11.028
103.
Munafò MR Thiselton DL Clark TG Flint J Association of the NRG1 gene and schizophrenia: a meta-analysisMol Psychiatry2006 11539546
Not in our library10.1038/sj.mp.4001817
104.
Munafò MR Attwood AS Flint J Neuregulin 1 genotype and schizophreniaSchizophr Bull2008 34912
Not in our library10.1093/schbul/sbm129
105.
Murphy KC Schizophrenia and velo-cardio-facial syndromeLancet2002 359426430
Not in our library10.1016/s0140-6736(02)07604-3
106.
Shifman S Bronstein M Sternfeld M Pisanté-Shalom A Lev-Lehman E Weizman A Reznik I Spivak B Grisaru N Karp L Schiffer R Kotler M Strous RD Swartz-Vanetik M Knobler HY Shinar E Beckmann JS Yakir B Risch N Zak NB Darvasi A A highly significant association between a COMT haplotype and schizophreniaAm J Hum Genet2002 7112961302
Not in our library10.1086/344514
107.
St Clair D Blackwood D Muir W Carothers A Walker M Spowart G Gosden C Evans HJ Association within a family of a balanced autosomal translocation with major mental illnessLancet1990 3361316
Not in our library10.1016/0140-6736(90)91520-k
108.
Blackwood DH Fordyce A Walker MT St Clair DM Porteous DJ Muir WJ Schizophrenia and affective disorders–cosegregation with a translocation at chromosome 1q42 that directly disrupts brain-expressed genes: clinical and P300 findings in a familyAm J Hum Genet2001 69428433
Not in our library10.1086/321969
109.
Millar JK Christie S Anderson S Lawson D Hsiao-Wei Loh D Devon RS Arveiler B Muir WJ Blackwood DH Porteous DJ Genomic structure and localisation within a linkage hotspot of Disrupted In Schizophrenia 1, a gene disrupted by a translocation segregating with schizophreniaMol Psychiatry2001 6173178
Not in our library10.1038/sj.mp.4000784
110.
Kim JY Duan X Liu CY Jang M-H Guo JU Pow-anpongkul N Kang E Song H Ming G DISC1 regulates new neuron development in the adult brain via modulation of AKT-mTOR signaling through KIAA1212Neuron2009 63761773
Not in our library10.1016/j.neuron.2009.08.008
111.
Kato T Molecular genetics of bipolar disorder and depressionPsychiatry Clin Neurosci2007 61319
Not in our library10.1111/j.1440-1819.2007.01604.x
112.
Callicott JH Straub RE Pezawas L Egan MF Mattay VS Hariri AR Verchinski BA Meyer-Lindenberg A Balkissoon R Kolachana B Goldberg TE Weinberger DR Variation in DISC1 affects hippocampal structure and function and increases risk for schizophreniaProc Natl Acad Sci USA2005 10286278632
Not in our library10.1073/pnas.0500515102
113.
Cannon TD Hennah W Van Erp TGM Thompson PM Lonnqvist J Huttunen M Gasperoni T Tuulio-Henriksson A Pirkola T Toga AW Kaprio J Mazziotta J Peltonen L Association of DISC1/TRAX haplotypes with schizophrenia, reduced prefrontal gray matter, and impaired short- and long-term memoryArch Gen Psychiatry2005 6212051213
Not in our library10.1001/archpsyc.62.11.1205
114.
Ekelund J Hennah W Hiekkalinna T Parker A Meyer J Lönnqvist J Peltonen L Replication of 1q42 linkage in Finnish schizophrenia pedigreesMol Psychiatry2004 910371041
Not in our library10.1038/sj.mp.4001536
115.
Hennah W Varilo T Kestilä M Paunio T Arajärvi R Haukka J Parker A Martin R Levitzky S Partonen T Meyer J Lönnqvist J Peltonen L Ekelund J Haplotype transmission analysis provides evidence of association for DISC1 to schizophrenia and suggests sex-dependent effectsHum Mol Genet2003 1231513159
Not in our library10.1093/hmg/ddg341
116.
Lepagnol-Bestel A-M Dubertret C Benmessaoud D Simonneau M Adès J Kacha F Hamdani N Gorwood P Ramoz N Association of DISC1 gene with schizophrenia in families from two distinct French and Algerian populationsPsychiatr Genet2010 20298303
Not in our library10.1097/ypg.0b013e32833aa5c4
117.
Rastogi A Zai C Likhodi O Kennedy JL Wong AH Genetic association and post-mortem brain mRNA analysis of DISC1 and related genes in schizophreniaSchizophr Res2009 1143949
Not in our library10.1016/j.schres.2009.06.019
118.
Liu Y-L Fann CS-J Liu C-M Chen WJ Wu J-Y Hung S-I Chen C-H Jou Y-S Liu S-K Hwang T-J Hsieh MH Ouyang W-C Chan H-Y Chen J-J Yang W-C Lin C-Y Lee SFC Hwu H-G A single nucleotide polymorphism fine mapping study of chromosome 1q42.1 reveals the vulnerability genes for schizophrenia, GNPAT and DISC1: Association with impairment of sustained attentionBiol Psychiatry2006 60554562
Not in our library10.1016/j.biopsych.2006.04.024
119.
Hennah W Thomson P McQuillin A Bass N Loukola A Anjorin A Blackwood D Curtis D Deary IJ Harris SE Isometsä ET Lawrence J Lönnqvist J Muir W Palotie A Partonen T Paunio T Pylkkö E Robinson M Soronen P Suominen K Suvisaari J Thirumalai S St Clair D Gurling H Peltonen L Porteous D DISC1 association, heterogeneity and interplay in schizophrenia and bipolar disorderMol Psychiatry2009 14865873
Not in our library10.1038/mp.2008.22
120.
Hodgkinson CA Goldman D Jaeger J Persaud S Kane JM Lipsky RH Malhotra AK Disrupted in schizophrenia 1 (DISC1): association with schizophrenia, schizoaffective disorder, and bipolar disorderAm J Hum Genet2004 75862872
Not in our library10.1086/425586
121.
Mata I Perez-Iglesias R Roiz-Santiañez R Tordesillas-Gutierrez D Gonzalez-Mandly A Berja A Vazquez-Barquero JL Crespo-Facorro B Additive effect of NRG1 and DISC1 genes on lateral ventricle enlargement in first episode schizophreniaNeuroimage2010 5310161022
Not in our library10.1016/j.neuroimage.2009.11.010
122.
Mouaffak F Kebir O Chayet M Tordjman S Vacheron MN Millet B Jaafari N Bellon A Olié JP Krebs M-O Association of Disrupted in Schizophrenia 1 (DISC1) missense variants with ultra-resistant schizophreniaPharmacogenomics J2011 11267273
Not in our library10.1038/tpj.2010.40
123.
Nicodemus KK Kolachana BS Vakkalanka R Straub RE Giegling I Egan MF Rujescu D Weinberger DR Evidence for statistical epistasis between catechol-O-methyltransferase (COMT) and polymorphisms in RGS4, G72 (DAOA), GRM3, and DISC1: influence on risk of schizophreniaHum Genet2007 120889906
Not in our library10.1007/s00439-006-0257-3
124.
Saetre P Agartz I De Franciscis A Lundmark P Djurovic S Kähler A Andreassen OA Jakobsen KD Rasmussen HB Werge T Hall H Terenius L Jönsson EG Association between a disrupted-in-schizophrenia 1 (DISC1) single nucleotide polymorphism and schizophrenia in a combined Scandinavian case–control sampleSchizophr Res2008 106237241
Not in our library10.1016/j.schres.2008.08.024
125.
Schumacher J Laje G Abou Jamra R Becker T Mühleisen TW Vasilescu C Mattheisen M Herms S Hoffmann P Hillmer AM Georgi A Herold C Schulze TG Propping P Rietschel M McMahon FJ Nöthen MM Cichon S The DISC locus and schizophrenia: evidence from an association study in a central European sample and from a meta-analysis across different European populationsHum Mol Genet2009 1827192727
Not in our library10.1093/hmg/ddp204
126.
Song W Li W Feng J Heston LL Scaringe WA Sommer SS Identification of high risk DISC1 structural variants with a 2% attributable risk for schizophreniaBiochem Biophys Res Commun2008 367700706
Not in our library10.1016/j.bbrc.2007.12.117
127.
Szeszko PR Hodgkinson CA Robinson DG Derosse P Bilder RM Lencz T Burdick KE Napolitano B Betensky JD Kane JM Goldman D Malhotra AK DISC1 is associated with prefrontal cortical gray matter and positive symptoms in schizophreniaBiol Psychol2008 79103110
Not in our library10.1016/j.biopsycho.2007.10.011
128.
Thomson PA Wray NR Millar JK Evans KL Hellard SL Condie A Muir WJ Blackwood DHR Porteous DJ Association between the TRAX/DISC locus and both bipolar disorder and schizophrenia in the Scottish populationMol Psychiatry2005 10657668616
Not in our library10.1038/sj.mp.4001669
129.
Wood LS Pickering EH Dechairo BM Significant support for DAO as a schizophrenia susceptibility locus: examination of five genes putatively associated with schizophreniaBiol Psychiatry2007 6111951199
Not in our library10.1016/j.biopsych.2006.07.005
130.
Zhang F Sarginson J Crombie C Walker N St Clair D Shaw D Genetic association between schizophrenia and the DISC1 gene in the Scottish populationAm J Med Genet B Neuropsychiatr Genet2006 141B155159
Not in our library10.1002/ajmg.b.30274
131.
Betcheva ET Mushiroda T Takahashi A Kubo M Karachanak SK Zaharieva IT Vazharova RV Dimova II Milanova VK Tolev T Kirov G Owen MJ O’Donovan MC Kamatani N Nakamura Y Toncheva DI Case–control association study of 59 candidate genes reveals the DRD2 SNP rs6277 (C957T) as the only susceptibility factor for schizophrenia in the Bulgarian populationJ Hum Genet2009 5498107
Not in our library10.1038/jhg.2008.14
132.
Devon RS Anderson S Teague PW Burgess P Kipari TM Semple CA Millar JK Muir WJ Murray V Pelosi AJ Blackwood DH Porteous DJ Identification of polymorphisms within Disrupted in Schizophrenia 1 and Disrupted in Schizophrenia 2, and an investigation of their association with schizophrenia and bipolar affective disorderPsychiatr Genet2001 117178
Not in our library10.1097/00041444-200106000-00003
133.
Crick F Central dogma of molecular biologyNature1970 227561563
Not in our library10.1038/227561a0
134.
Pastori C Wahlestedt C Involvement of long noncoding RNAs in diseases affecting the central nervous systemRNA Biol2012 9860870
Not in our library10.4161/rna.20482
135.
Elgar G Vavouri T Tuning in to the signals: noncoding sequence conservation in vertebrate genomesTrends Genet2008 24344352
Not in our library10.1016/j.tig.2008.04.005
136.
Bird A Perceptions of epigeneticsNature2007 447396398
Not in our library10.1038/nature05913
137.
The emerging role of non-coding RNAs in drug addiction · 2012
Not checked
138.
Tsankova N Renthal W Kumar A Nestler EJ Epigenetic regulation in psychiatric disordersNat Rev Neurosci2007 8355367
Not in our library10.1038/nrn2132
139.
Nemeroff CB The burden of severe depression: A review of diagnostic challenges and treatment alternativesJ Psychiatr Res2007 41189206
Not in our library10.1016/j.jpsychires.2006.05.008
140.
Tsankova NM Berton O Renthal W Kumar A Neve RL Nestler EJ Sustained hippocampal chromatin regulation in a mouse model of depression and antidepressant actionNat Neurosci2006 9519525
Not in our library10.1038/nn1659
141.
Meaney MJ Szyf M Maternal care as a model for experience-dependent chromatin plasticity?Trends Neurosci2005 28456463
Not in our library10.1016/j.tins.2005.07.006
142.
Champagne FA Francis DD Mar A Meaney MJ Variations in maternal care in the rat as a mediating influence for the effects of environment on developmentPhysiol Behav2003 79359371
Not in our library10.1016/s0031-9384(03)00149-5
143.
Schroeder M Krebs MO Bleich S Frieling H Epigenetics and depression: current challenges and new therapeutic optionsCurr Opin Psychiatry2010 23588592
Not in our library10.1097/yco.0b013e32833d16c1
144.
McGowan PO Sasaki A D’Alessio AC Dymov S Labonté B Szyf M Turecki G Meaney MJ Epigenetic regulation of the glucocorticoid receptor in human brain associates with childhood abuseNat Neurosci2009 12342348
Not in our library10.1038/nn.2270
145.
Pollin W Cardon PV Jr Kety SS Effects of amino acid feedings in schizophrenic patients treated with iproniazidScience1961 133104105
Not in our library10.1126/science.133.3446.104
146.
Brune GG Himwich HE Effects of methionine loading on the behavior of schizophrenic patientsJ Nerv Ment Dis1962 134447450
Not in our library10.1097/00005053-196205000-00007
147.
D’Arcangelo G Miao GG Chen SC Soares HD Morgan JI Curran T A protein related to extracellular matrix proteins deleted in the mouse mutant reelerNature1995 374719723
Not in our library10.1038/374719a0
148.
Abdolmaleky HM Cheng K-H Faraone SV Wilcox M Glatt SJ Gao F Smith CL Shafa R Aeali B Carnevale J Pan H Papageorgis P Ponte JF Sivaraman V Tsuang MT Thiagalingam S Hypomethylation of MB-COMT promoter is a major risk factor for schizophrenia and bipolar disorderHum Mol Genet2006 1531323145
Not in our library10.1093/hmg/ddl253
149.
Grayson DR Chen Y Costa E Dong E Guidotti A Kundakovic M Sharma RP The human reelin gene: transcription factors (+), repressors (−) and the methylation switch (+/−) in schizophreniaPharmacol Ther2006 111272286
Not in our library10.1016/j.pharmthera.2005.01.007
150.
Abdolmaleky HM Cheng K Russo A Smith CL Faraone SV Wilcox M Shafa R Glatt SJ Nguyen G Ponte JF Thiagalingam S Tsuang MT Hypermethylation of the reelin (RELN) promoter in the brain of schizophrenic patients: a preliminary reportAm J Med Genet B Neuropsychiatr Genet2005 134B6066
Not in our library10.1002/ajmg.b.30140
151.
Mill J Tang T Kaminsky Z Khare T Yazdanpanah S Bouchard L Jia P Assadzadeh A Flanagan J Schumacher A Wang S-C Petronis A Epigenomic profiling reveals DNA-methylation changes associated with major psychosisAm J Hum Genet2008 82696711
Not in our library10.1016/j.ajhg.2008.01.008
152.
Tochigi M Iwamoto K Bundo M Komori A Sasaki T Kato N Kato T Methylation status of the reelin promoter region in the brain of schizophrenic patientsBiol Psychiatry2008 63530533
Not in our library10.1016/j.biopsych.2007.07.003
153.
Abdolmaleky HM Faraone SV Glatt SJ Tsuang MT Meta-analysis of association between the T102C polymorphism of the 5HT2a receptor gene and schizophreniaSchizophr Res2004 675362
Not in our library10.1016/s0920-9964(03)00183-x
154.
Abdolmaleky HM Smith CL Faraone SV Shafa R Stone W Glatt SJ Tsuang MT Methylomics in psychiatry: Modulation of gene-environment interactions may be through DNA methylationAm J Med Genet B Neuropsychiatr Genet2004 127B5159
Not in our library10.1002/ajmg.b.20142
155.
Levinson DF Meta-analysis in psychiatric geneticsCurr Psychiatry Rep2005 7143151
Not in our library10.1007/s11920-005-0012-9
156.
Polesskaya OO Aston C Sokolov BP Allele C-specific methylation of the 5-HT2A receptor gene: evidence for correlation with its expression and expression of DNA methylase DNMT1J Neurosci Res2006 83362373
Not in our library10.1002/jnr.20732
157.
Polesskaya OO Sokolov BP Differential expression of the “C” and “T” alleles of the 5-HT2A receptor gene in the temporal cortex of normal individuals and schizophrenicsJ Neurosci Res2002 67812822
Not in our library10.1002/jnr.10173
158.
Falkenberg VR Gurbaxani BM Unger ER Rajeevan MS Functional genomics of serotonin receptor 2A (HTR2A): interaction of polymorphism, methylation, expression and disease associationNeuromolecular Med2011 136676
Not in our library10.1007/s12017-010-8138-2
159.
Thiagalingam S Cheng K-H Lee HJ Mineva N Thiagalingam A Ponte JF Histone deacetylases: unique players in shaping the epigenetic histone codeAnn N Y Acad Sci2003 98384100
Not in our library10.1111/j.1749-6632.2003.tb05964.x
160.
Sharma RP Grayson DR Gavin DP Histone deactylase 1 expression is increased in the prefrontal cortex of schizophrenia subjects: analysis of the National Brain Databank microarray collectionSchizophr Res2008 98111117
Not in our library10.1016/j.schres.2007.09.020
161.
Benes FM Lim B Matzilevich D Subburaju S Walsh JP Circuitry-based gene expression profiles in GABA cells of the trisynaptic pathway in schizophrenics versus bipolarsProc Natl Acad Sci USA2008 1052093520940
Not in our library10.1073/pnas.0810153105
162.
Guidotti A Auta J Davis JM Di-Giorgi-Gerevini V Dwivedi Y Grayson DR Impagnatiello F Pandey G Pesold C Sharma R Uzunov D Costa E DiGiorgi GV Decrease in reelin and glutamic acid decarboxylase67 (GAD67) expression in schizophrenia and bipolar disorder: a postmortem brain studyArch Gen Psychiatry2000 5710611069
Not in our library10.1001/archpsyc.57.11.1061
163.
Heckers S Stone D Walsh J Shick J Koul P Benes FM Differential hippocampal expression of glutamic acid decarboxylase 65 and 67 messenger RNA in bipolar disorder and schizophreniaArch Gen Psychiatry2002 59521529
Not in our library10.1001/archpsyc.59.6.521
164.
Woo T-UW Walsh JP Benes FM Density of glutamic acid decarboxylase 67 messenger RNA-containing neurons that express the N-methyl-D-aspartate receptor subunit NR2A in the anterior cingulate cortex in schizophrenia and bipolar disorderArch Gen Psychiatry2004 61649657
Not in our library10.1001/archpsyc.61.7.649
165.
Fatemi SH Hossein Fatemi S Stary JM Earle JA Araghi-Niknam M Eagan E GABAergic dysfunction in schizophrenia and mood disorders as reflected by decreased levels of glutamic acid decarboxylase 65 and 67 kDa and Reelin proteins in cerebellumSchizophr Res2005 72109122
Not in our library10.1016/j.schres.2004.02.017
166.
Tremolizzo L Doueiri M-S Dong E Grayson DR Davis J Pinna G Tueting P Rodriguez-Menendez V Costa E Guidotti A Valproate corrects the schizophrenia-like epigenetic behavioral modifications induced by methionine in miceBiol Psychiatry2005 57500509
Not in our library10.1016/j.biopsych.2004.11.046
167.
Göttlicher M Valproic acid: an old drug newly discovered as inhibitor of histone deacetylasesAnn Hematol2004 83S9192
Not in our library10.1007/s00277-004-0850-2
168.
Bartel DP MicroRNAs: genomics, biogenesis, mechanism, and functionCell2004 116281297
Not in our library10.1016/s0092-8674(04)00045-5
169.
Miller BH Wahlestedt C MicroRNA dysregulation in psychiatric diseaseBrain Res2010 13388999
Not in our library10.1016/j.brainres.2010.03.035
170.
microRNA expression in the prefrontal cortex of individuals with schizophrenia and schizoaffective disorder · 2007
No notice
171.
Beveridge NJ Tooney PA Carroll AP Gardiner E Bowden N Scott RJ Tran N Dedova I Cairns MJ Dysregulation of miRNA 181b in the temporal cortex in schizophreniaHum Mol Genet2008 1711561168
Not in our library10.1093/hmg/ddn005
172.
Beveridge NJ Gardiner E Carroll AP Tooney PA Cairns MJ Schizophrenia is associated with an increase in cortical microRNA biogenesisMol Psychiatry2010 1511761189
Not in our library10.1038/mp.2009.84
173.
Miller BH Zeier Z Xi L Lanz TA Deng S Strathmann J Willoughby D Kenny PJ Elsworth JD Lawrence MS Roth RH Edbauer D Kleiman RJ Wahlestedt C MicroRNA-132 dysregulation in schizophrenia has implications for both neurodevelopment and adult brain functionProc Natl Acad Sci USA2012 10931253130
Not in our library10.1073/pnas.1113793109
174.
Gottesman II Gould TD The endophenotype concept in psychiatry: etymology and strategic intentionsAm J Psychiatry2003 160636645
Not in our library10.1176/appi.ajp.160.4.636
175.
Beauchaine TP Role of biomarkers and endophenotypes in prevention and treatment of psychopathological disordersBiomark Med2009 313
Not in our library10.2217/17520363.3.1.1
176.
Biomarkers Definitions Working GroupBiomarkers and surrogate endpoints: preferred definitions and conceptual frameworkClin Pharmacol Ther2001 698995
Not in our library10.1067/mcp.2001.113989
177.
Kraemer HC Schultz SK Arndt S Biomarkers in psychiatry: methodological issuesAm J Geriatr Psychiatry2002 10653659
Not in our library
178.
Wichers M Myin-Germeys I Jacobs N Peeters F Kenis G Derom C Vlietinck R Delespaul P Van Os J Genetic risk of depression and stress-induced negative affect in daily lifeBr J Psychiatry2007 191218223
Not in our library10.1192/bjp.bp.106.032201
179.
Ellwart T Rinck M Becker ES Selective memory and memory deficits in depressed inpatientsDepress Anxiety2003 17197206
Not in our library10.1002/da.10102
180.
Tarsia M Power MJ Sanavio E Implicit and explicit memory biases in mixed anxiety-depressionJ Affect Disord2003 77213225
Not in our library10.1016/s0165-0327(02)00119-2
181.
Erickson K Drevets WC Clark L Cannon DM Bain EE Zarate CA Jr Charney DS Sahakian BJ Mood-congruent bias in affective go/no-go performance of unmedicated patients with major depressive disorderAm J Psychiatry2005 16221712173
Not in our library10.1176/appi.ajp.162.11.2171
182.
Koster EHW De Raedt R Leyman L De Lissnyder E Mood-congruent attention and memory bias in dysphoria: Exploring the coherence among information-processing biasesBehav Res Ther2010 48219225
Not in our library10.1016/j.brat.2009.11.004
183.
Van Wingen GA Van Eijndhoven P Cremers HR Tendolkar I Verkes RJ Buitelaar JK Fernández G Neural state and trait bases of mood-incongruent memory formation and retrieval in first-episode major depressionJ Psychiatr Res2010 44527534
Not in our library10.1016/j.jpsychires.2009.11.009
184.
Dryman A Eaton WW Affective symptoms associated with the onset of major depression in the community: findings from the US National Institute of Mental Health Epidemiologic Catchment Area ProgramActa Psychiatr Scand1991 8415
Not in our library10.1111/j.1600-0447.1991.tb01410.x
185.
Hirschfeld RM Klerman GL Clayton PJ Keller MB Personality and depression. Empirical findingsArch Gen Psychiatry1983 40993998
Not in our library10.1001/archpsyc.1983.01790080075010
186.
Schrader GD Does anhedonia correlate with depression severity in chronic depression?Compr Psychiatry1997 38260263
Not in our library10.1016/s0010-440x(97)90057-2
187.
Hecht H Van Calker D Berger M Von Zerssen D Personality in patients with affective disorders and their relativesJ Affect Disord1998 513343
Not in our library10.1016/s0165-0327(98)00154-2
188.
McCabe C Cowen PJ Harmer CJ Neural representation of reward in recovered depressed patientsPsychopharmacology (Berl)2009 205667677
Not in our library10.1007/s00213-009-1573-9
189.
Lester D The concentration of neurotransmitter metabolites in the cerebrospinal fluid of suicidal individuals: a meta-analysisPharmacopsychiatry1995 284550
Not in our library10.1055/s-2007-979587
190.
Galfalvy H Currier D Oquendo MA Sullivan G Huang Y-Y John Mann J Lower CSF MHPG predicts short-term risk for suicide attemptInt J Neuropsychopharmacol2009 1213271335
Not in our library10.1017/s1461145709990228
191.
Ramel W Goldin PR Eyler LT Brown GG Gotlib IH McQuaid JR Amygdala reactivity and mood-congruent memory in individuals at risk for depressive relapseBiol Psychiatry2007 61231239
Not in our library10.1016/j.biopsych.2006.05.004
192.
Poo MM Neurotrophins as synaptic modulatorsNat Rev Neurosci2001 22432
Not in our library10.1038/35049004
193.
Autry AE Monteggia LM Brain-derived neurotrophic factor and neuropsychiatric disordersPharmacol Rev2012 64238258
Not in our library10.1124/pr.111.005108
194.
Karege F Bondolfi G Gervasoni N Schwald M Aubry J-M Bertschy G Low brain-derived neurotrophic factor (BDNF) levels in serum of depressed patients probably results from lowered platelet BDNF release unrelated to platelet reactivityBiol Psychiatry2005 5710681072
Not in our library10.1016/j.biopsych.2005.01.008
195.
Pan W Banks WA Fasold MB Bluth J Kastin AJ Transport of brain-derived neurotrophic factor across the blood–brain barrierNeuropharmacology1998 3715531561
Not in our library10.1016/s0028-3908(98)00141-5
196.
Fernandes BS Gama CS Ceresér KM Yatham LN Fries GR Colpo G De Lucena D Kunz M Gomes FA Kapczinski F Brain-derived neurotrophic factor as a state-marker of mood episodes in bipolar disorders: a systematic review and meta-regression analysisJ Psychiatr Res2011 459951004
Not in our library10.1016/j.jpsychires.2011.03.002
197.
Lin P-Y State-dependent decrease in levels of brain-derived neurotrophic factor in bipolar disorder: a meta-analytic studyNeurosci Lett2009 466139143
Not in our library10.1016/j.neulet.2009.09.044
198.
Fernandes BS Gama CS Kauer-Sant’Anna M Lobato MI Belmonte-de-Abreu P Kapczinski F Serum brain-derived neurotrophic factor in bipolar and unipolar depression: a potential adjunctive tool for differential diagnosisJ Psychiatr Res2009 4312001204
Not in our library10.1016/j.jpsychires.2009.04.010
199.
Wehr TA Goodwin FK Can antidepressants cause mania and worsen the course of affective illness?Am J Psychiatry1987 14414031411
Not in our library10.1176/ajp.144.11.1403
200.
Bora E Yucel M Pantelis C Cognitive endophenotypes of bipolar disorder: a meta-analysis of neuropsychological deficits in euthymic patients and their first-degree relativesJ Affect Disord2009 113120
Not in our library10.1016/j.jad.2008.06.009
201.
Snitz BE Macdonald AW 3rd Carter CS Cognitive deficits in unaffected first-degree relatives of schizophrenia patients: a meta-analytic review of putative endophenotypesSchizophr Bull2006 32179194
Not in our library10.1093/schbul/sbi048
202.
Gur RE Nimgaonkar VL Almasy L Calkins ME Ragland JD Pogue-Geile MF Kanes S Blangero J Gur RC Neurocognitive endophenotypes in a multiplex multigenerational family study of schizophreniaAm J Psychiatry2007 164813819
Not in our library10.1176/ajp.2007.164.5.813
203.
Sitskoorn MM Aleman A Ebisch SJH Appels MCM Kahn RS Cognitive deficits in relatives of patients with schizophrenia: a meta-analysisSchizophr Res2004 71285295
Not in our library10.1016/j.schres.2004.03.007
204.
Szöke A Schürhoff F Mathieu F Meary A Ionescu S Leboyer M Tests of executive functions in first-degree relatives of schizophrenic patients: a meta-analysisPsychol Med2005 35771782
Not in our library10.1017/s0033291704003460
205.
Fioravanti M Carlone O Vitale B Cinti ME Clare L A meta-analysis of cognitive deficits in adults with a diagnosis of schizophreniaNeuropsychol Rev2005 157395
Not in our library10.1007/s11065-005-6254-9
206.
Saykin AJ Gur RC Gur RE Mozley PD Mozley LH Resnick SM Kester DB Stafiniak P Neuropsychological function in schizophrenia, Selective impairment in memory and learningArch Gen Psychiatry1991 48618624
Not in our library10.1001/archpsyc.1991.01810310036007
207.
Egan MF Goldberg TE Gscheidle T Weirich M Rawlings R Hyde TM Bigelow L Weinberger DR Relative risk for cognitive impairments in siblings of patients with schizophreniaBiol Psychiatry2001 5098107
Not in our library10.1016/s0006-3223(01)01133-7
208.
Cannon TD Zorrilla LE Shtasel D Gur RE Gur RC Marco EJ Moberg P Price RA Neuropsychological functioning in siblings discordant for schizophrenia and healthy volunteersArch Gen Psychiatry1994 51651661
Not in our library10.1001/archpsyc.1994.03950080063009
209.
Faraone SV Seidman LJ Kremen WS Pepple JR Lyons MJ Tsuang MT Neuropsychological functioning among the nonpsychotic relatives of schizophrenic patients: a diagnostic efficiency analysisJ Abnorm Psychol1995 104286304
Not in our library10.1037//0021-843x.104.2.286
210.
Conklin HM Curtis CE Calkins ME Iacono WG Working memory functioning in schizophrenia patients and their first-degree relatives: cognitive functioning shedding light on etiologyNeuropsychologia2005 43930942
Not in our library10.1016/j.neuropsychologia.2004.09.013
211.
Gibbons JL McHugh PR Plasma cortisol in depressive illnessJ Psychiatr Res1962 1162171
Not in our library10.1016/0022-3956(62)90006-7
212.
Carpenter WT Jr Bunney WE Jr Adrenal cortical activity in depressive illnessAm J Psychiatry1971 1283140
Not in our library10.1176/ajp.128.1.31
213.
Swanson LW Sawchenko PE Rivier J Vale WW Organization of ovine corticotropin-releasing factor immunoreactive cells and fibers in the rat brain: an immunohistochemical studyNeuroendocrinology1983 36165186
Not in our library10.1159/000123454
214.
Arborelius L Owens MJ Plotsky PM Nemeroff CB The role of corticotropin-releasing factor in depression and anxiety disordersJ Endocrinol1999 160112
Not in our library10.1677/joe.0.1600001
215.
Dunn AJ Berridge CW Physiological and behavioral responses to corticotropin-releasing factor administration: is CRF a mediator of anxiety or stress responses?Brain Res Brain Res Rev1990 1571100
Not in our library10.1016/0165-0173(90)90012-d
216.
Owens MJ Nemeroff CB Physiology and pharmacology of corticotropin-releasing factorPharmacol Rev1991 43425473
Not in our library
217.
Bradley RG Binder EB Epstein MP Tang Y Nair HP Liu W Gillespie CF Berg T Evces M Newport DJ Stowe ZN Heim CM Nemeroff CB Schwartz A Cubells JF Ressler KJ Influence of child abuse on adult depression: moderation by the corticotropin-releasing hormone receptor geneArch Gen Psychiatry2008 65190200
Not in our library10.1001/archgenpsychiatry.2007.26
218.
Polanczyk G Caspi A Williams B Price TS Danese A Sugden K Uher R Poulton R Moffitt TE Protective effect of CRHR1 gene variants on the development of adult depression following childhood maltreatment: replication and extensionArch Gen Psychiatry2009 66978985
Not in our library10.1001/archgenpsychiatry.2009.114
219.
Tyrka AR Price LH Gelernter J Schepker C Anderson GM Carpenter LL Interaction of childhood maltreatment with the corticotropin-releasing hormone receptor gene: effects on hypothalamic-pituitary-adrenal axis reactivityBiol Psychiatry2009 66681685
Not in our library10.1016/j.biopsych.2009.05.012
220.
Heim C Bradley B Mletzko TC Deveau TC Musselman DL Nemeroff CB Ressler KJ Binder EB Effect of Childhood Trauma on Adult Depression and Neuroendocrine Function: Sex-Specific Moderation by CRH Receptor 1 GeneFront Behav Neurosci2009 341
Not in our library10.3389/neuro.08.041.2009
221.
Caspi A Sugden K Moffitt TE Taylor A Craig IW Harrington H McClay J Mill J Martin J Braithwaite A Poulton R Influence of life stress on depression: moderation by a polymorphism in the 5-HTT geneScience2003 301386389
Not in our library10.1126/science.1083968
222.
McGuffin P Asherson P Owen M Farmer A The strength of the genetic effect. Is there room for an environmental influence in the aetiology of schizophrenia?Br J Psychiatry1994 164593599
Not in our library10.1192/bjp.164.5.593
223.
Stabenau JR Pollin W Early characteristics of monozygotic twins discordant for schizophreniaArch Gen Psychiatry1967 17723734
Not in our library10.1001/archpsyc.1967.01730300083011
224.
Cannon M Jones PB Murray RM Obstetric complications and schizophrenia: historical and meta-analytic reviewAm J Psychiatry2002 15910801092
Not in our library10.1176/appi.ajp.159.7.1080
225.
Scott J McNeill Y Cavanagh J Cannon M Murray R Exposure to obstetric complications and subsequent development of bipolar disorder: Systematic reviewBr J Psychiatry2006 189311
Not in our library10.1192/bjp.bp.105.010579
226.
Mednick SA Machon RA Huttunen MO Bonett D Adult schizophrenia following prenatal exposure to an influenza epidemicArch Gen Psychiatry1988 45189192
Not in our library10.1001/archpsyc.1988.01800260109013
227.
O’Callaghan E Sham P Takei N Glover G Murray RM Schizophrenia after prenatal exposure to 1957 A2 influenza epidemicLancet1991 33712481250
Not in our library10.1016/0140-6736(91)92919-s
228.
Brown AS Prenatal infection as a risk factor for schizophreniaSchizophr Bull2006 32200202
Not in our library10.1093/schbul/sbj052
229.
Selten J-P Frissen A Lensvelt-Mulders G Morgan VA Schizophrenia and 1957 pandemic of influenza: meta-analysisSchizophr Bull2010 36219228
Not in our library10.1093/schbul/sbp147
230.
Selten J-P Cantor-Graae E Nahon D Levav I Aleman A Kahn RS No relationship between risk of schizophrenia and prenatal exposure to stress during the Six-Day War or Yom Kippur War in IsraelSchizophr Res2003 63131135
Not in our library10.1016/s0920-9964(02)00375-4
231.
Ferguson CS Tyndale RF Cytochrome P450 enzymes in the brain: emerging evidence of biological significanceTrends Pharmacol Sci2011 32708714
Not in our library10.1016/j.tips.2011.08.005
232.
Stingl JC Brockmöller J Viviani R Genetic variability of drug-metabolizing enzymes: the dual impact on psychiatric therapy and regulation of brain functionMol Psychiatry2013 18273287
Not in our library10.1038/mp.2012.42
233.
Bromek E Haduch A Gołembiowska K Daniel WA Cytochrome P450 mediates dopamine formation in the brain in vivoJ Neurochem2011 118806815
Not in our library10.1111/j.1471-4159.2011.07339.x
234.
Yu A-M Idle JR Byrd LG Krausz KW Küpfer A Gonzalez FJ Regeneration of serotonin from 5-methoxytryptamine by polymorphic human CYP2D6Pharmacogenetics2003 13173181
Not in our library10.1097/01.fpc.0000054066.98065.7b
235.
Nemeroff CB DeVane CL Pollock BG Newer antidepressants and the cytochrome P450 systemAm J Psychiatry1996 153311320
Not in our library10.1176/ajp.153.3.311
236.
Thakur M Grossman I McCrory DC Orlando LA Steffens DC Cline KE Gray RN Farmer J DeJesus G O’Brien C Samsa G Goldstein DB Matchar DB Review of evidence for genetic testing for CYP450 polymorphisms in management of patients with nonpsychotic depression with selective serotonin reuptake inhibitorsGenet Med2007 9826835
Not in our library10.1097/gim.0b013e31815bf98f
237.
Fleeman N McLeod C Bagust A Beale S Boland A Dundar Y Jorgensen A Payne K Pirmohamed M Pushpakom S Walley T De Warren-Penny P Dickson R The clinical effectiveness and cost-effectiveness of testing for cytochrome P450 polymorphisms in patients with schizophrenia treated with antipsychotics: a systematic review and economic evaluationHealth Technol Assess2010 141157iii
Not in our library10.3310/hta14030
238.
Fleeman N Dundar Y Dickson R Jorgensen A Pushpakom S McLeod C Pirmohamed M Walley T Cytochrome P450 testing for prescribing antipsychotics in adults with schizophrenia: systematic review and meta-analysesPharmacogenomics J2011 11114
Not in our library10.1038/tpj.2010.73
239.
Porcelli S Drago A Fabbri C Gibiino S Calati R Serretti A Pharmacogenetics of antidepressant responseJ Psychiatry Neurosci2011 3687113
Not in our library10.1503/jpn.100059
240.
Mrazek DA Rush AJ Biernacka JM O’Kane DJ Cunningham JM Wieben ED Schaid DJ Drews MS Courson VL Snyder KA Black JL 3rd Weinshilboum RM SLC6A4 variation and citalopram responseAm J Med Genet B Neuropsychiatr Genet2009 150B341351
Not in our library10.1002/ajmg.b.30816
241.
Min W Li T Ma X Li Z Yu T Gao D Zhang B Yun Y Sun X Monoamine transporter gene polymorphisms affect susceptibility to depression and predict antidepressant responsePsychopharmacology (Berl)2009 205409417
Not in our library10.1007/s00213-009-1550-3
242.
Huezo-Diaz P Uher R Smith R Rietschel M Henigsberg N Marusic A Mors O Maier W Hauser J Souery D Placentino A Zobel A Larsen ER Czerski PM Gupta B Hoda F Perroud N Farmer A Craig I Aitchison KJ McGuffin P Moderation of antidepressant response by the serotonin transporter geneBr J Psychiatry2009 1953038
Not in our library10.1192/bjp.bp.108.062521
243.
Bozina N Peles AM Sagud M Bilusic H Jakovljevic M Association study of paroxetine therapeutic response with SERT gene polymorphisms in patients with major depressive disorderWorld J Biol Psychiatry2008 9190197
Not in our library10.1080/15622970701308397
244.
Smeraldi E Serretti A Artioli P Lorenzi C Catalano M Serotonin transporter gene-linked polymorphic region: possible pharmacogenetic implications of rare variantsPsychiatr Genet2006 16153158
Not in our library10.1097/01.ypg.0000218611.53064.a0
245.
Smeraldi E Zanardi R Benedetti F Di Bella D Perez J Catalano M Polymorphism within the promoter of the serotonin transporter gene and antidepressant efficacy of fluvoxamineMol Psychiatry1998 3508511
Not in our library10.1038/sj.mp.4000425
246.
Hong C-J Chen T-J Yu YW-Y Tsai S-J Response to fluoxetine and serotonin 1A receptor (C-1019G) polymorphism in Taiwan Chinese major depressive disorderPharmacogenomics J2006 62733
Not in our library10.1038/sj.tpj.6500340
247.
Kato M Fukuda T Wakeno M Fukuda K Okugawa G Ikenaga Y Yamashita M Takekita Y Nobuhara K Azuma J Kinoshita T Effects of the serotonin type 2A, 3A and 3B receptor and the serotonin transporter genes on paroxetine and fluvoxamine efficacy and adverse drug reactions in depressed Japanese patientsNeuropsychobiology2006 53186195
Not in our library10.1159/000094727
248.
Kato M Ikenaga Y Wakeno M Okugawa G Nobuhara K Fukuda T Fukuda K Azuma J Kinoshita T Controlled clinical comparison of paroxetine and fluvoxamine considering the serotonin transporter promoter polymorphismInt Clin Psychopharmacol2005 20151156
Not in our library10.1097/00004850-200505000-00005
249.
Rausch JL Johnson ME Fei Y-J Li JQ Shendarkar N Hobby HM Ganapathy V Leibach FH Initial conditions of serotonin transporter kinetics and genotype: influence on SSRI treatment trial outcomeBiol Psychiatry2002 51723732
Not in our library10.1016/s0006-3223(01)01283-5
250.
Zanardi R Serretti A Rossini D Franchini L Cusin C Lattuada E Dotoli D Smeraldi E Factors affecting fluvoxamine antidepressant activity: influence of pindolol and 5-HTTLPR in delusional and nondelusional depressionBiol Psychiatry2001 50323330
Not in our library10.1016/s0006-3223(01)01118-0
251.
Serretti A Cusin C Rossini D Artioli P Dotoli D Zanardi R Further evidence of a combined effect of SERTPR and TPH on SSRIs response in mood disordersAm J Med Genet B Neuropsychiatr Genet2004 129B3640
Not in our library10.1002/ajmg.b.30027
252.
Murphy GM Jr Hollander SB Rodrigues HE Kremer C Schatzberg AF Effects of the serotonin transporter gene promoter polymorphism on mirtazapine and paroxetine efficacy and adverse events in geriatric major depressionArch Gen Psychiatry2004 6111631169
Not in our library10.1001/archpsyc.61.11.1163
253.
Smits K Smits L Peeters F Schouten J Janssen R Smeets H Van Os J Prins M Serotonin transporter polymorphisms and the occurrence of adverse events during treatment with selective serotonin reuptake inhibitorsInt Clin Psychopharmacol2007 22137143
Not in our library10.1097/yic.0b013e328014822a
254.
Smits KM Smits LJM Peeters FPML Schouten JSAG Janssen RGJH Smeets HJM Van Os J Prins MH The influence of 5-HTTLPR and STin2 polymorphisms in the serotonin transporter gene on treatment effect of selective serotonin reuptake inhibitors in depressive patientsPsychiatr Genet2008 18184190
Not in our library10.1097/ypg.0b013e3283050aca
255.
Durham LK Webb SM Milos PM Clary CM Seymour AB The serotonin transporter polymorphism, 5HTTLPR, is associated with a faster response time to sertraline in an elderly population with major depressive disorderPsychopharmacology (Berl)2004 174525529
Not in our library10.1007/s00213-003-1562-3
256.
Arias B Catalán R Gastó C Gutiérrez B Fañanás L 5-HTTLPR polymorphism of the serotonin transporter gene predicts non-remission in major depression patients treated with citalopram in a 12-weeks follow up studyJ Clin Psychopharmacol2003 23563567
Not in our library10.1097/01.jcp.0000095350.32154.73
257.
Joyce PR Mulder RT Luty SE McKenzie JM Miller AL Rogers GR Kennedy MA Age-dependent antidepressant pharmacogenomics: polymorphisms of the serotonin transporter and G protein beta3 subunit as predictors of response to fluoxetine and nortriptylineInt J Neuropsychopharmacol2003 6339346
Not in our library10.1017/s1461145703003663
258.
Pollock BG Ferrell RE Mulsant BH Mazumdar S Miller M Sweet RA Davis S Kirshner MA Houck PR Stack JA Reynolds CF Kupfer DJ Allelic variation in the serotonin transporter promoter affects onset of paroxetine treatment response in late-life depressionNeuropsychopharmacology2000 23587590
Not in our library10.1016/s0893-133x(00)00132-9
259.
Kim H Lim S-W Kim S Kim J-W Chang YH Carroll BJ Kim DK Monoamine transporter gene polymorphisms and antidepressant response in koreans with late-life depressionJAMA2006 29616091618
Not in our library10.1001/jama.296.13.1609
260.
Yoshida K Takahashi H Higuchi H Kamata M Ito K Sato K Naito S Shimizu T Itoh K Inoue K Suzuki T Nemeroff CB Prediction of antidepressant response to milnacipran by norepinephrine transporter gene polymorphismsAm J Psychiatry2004 16115751580
Not in our library10.1176/appi.ajp.161.9.1575
261.
Lotrich FE Pollock BG Kirshner M Ferrell RF Reynolds Iii CF: Serotonin transporter genotype interacts with paroxetine plasma levels to influence depression treatment response in geriatric patientsJ Psychiatry Neurosci2008 33123130
Not in our library
262.
Yoshimura R Umene-Nakano W Suzuki A Ueda N Miyamoto K Ikenouchi-Sugita A Hori H Otani K Nakamura J Rapid response to paroxetine is associated with plasma paroxetine levels at 4 but not 8 weeks of treatment, and is independent of serotonin transporter promoter polymorphism in Japanese depressed patientsHum Psychopharmacol2009 24489494
Not in our library10.1002/hup.1043
263.
Ng CH Easteal S Tan S Schweitzer I Ho BKW Aziz S Serotonin transporter polymorphisms and clinical response to sertraline across ethnicitiesProg Neuropsychopharmacol Biol Psychiatry2006 30953957
Not in our library10.1016/j.pnpbp.2006.02.015
264.
Yu YW-Y Tsai S-J Liou Y-J Hong C-J Chen T-J Association study of two serotonin 1A receptor gene polymorphisms and fluoxetine treatment response in Chinese major depressive disordersEur Neuropsychopharmacol2006 16498503
Not in our library10.1016/j.euroneuro.2005.12.004
265.
Serretti A Artioli P Lorenzi C Pirovano A Tubazio V Zanardi R The C(−1019)G polymorphism of the 5-HT1A gene promoter and antidepressant response in mood disorders: preliminary findingsInt J Neuropsychopharmacol2004 7453460
Not in our library10.1017/s1461145704004687
266.
Kato M Fukuda T Wakeno M Okugawa G Takekita Y Watanabe S Yamashita M Hosoi Y Azuma J Kinoshita T Serretti A Effect of 5-HT1A gene polymorphisms on antidepressant response in major depressive disorderAm J Med Genet B Neuropsychiatr Genet2009 150B115123
Not in our library10.1002/ajmg.b.30783
267.
Levin GM Bowles TM Ehret MJ Langaee T Tan JY Johnson JA Millard WJ Assessment of human serotonin 1A receptor polymorphisms and SSRI responsivenessMol Diagn Ther2007 11155160
Not in our library10.1007/bf03256237
268.
Suzuki Y Sawamura K Someya T Polymorphisms in the 5-hydroxytryptamine 2A receptor and CytochromeP4502D6 genes synergistically predict fluvoxamine-induced side effects in japanese depressed patientsNeuropsychopharmacology2006 31825831
Not in our library10.1038/sj.npp.1300919
269.
Peters EJ Slager SL McGrath PJ Knowles JA Hamilton SP Investigation of serotonin-related genes in antidepressant responseMol Psychiatry2004 9879889
Not in our library10.1038/sj.mp.4001502
270.
Uher R Huezo-Diaz P Perroud N Smith R Rietschel M Mors O Hauser J Maier W Kozel D Henigsberg N Barreto M Placentino A Dernovsek MZ Schulze TG Kalember P Zobel A Czerski PM Larsen ER Souery D Giovannini C Gray JM Lewis CM Farmer A Aitchison KJ McGuffin P Craig I Genetic predictors of response to antidepressants in the GENDEP projectPharmacogenomics J2009 9225233
Not in our library10.1038/tpj.2009.12
271.
Peters EJ Slager SL Jenkins GD Reinalda MS Garriock HA Shyn SI Kraft JB McGrath PJ Hamilton SP Resequencing of serotonin-related genes and association of tagging SNPs to citalopram responsePharmacogenet Genomics2009 19110
Not in our library10.1097/fpc.0b013e3283163ecd
272.
Wilkie MJV Smith G Day RK Matthews K Smith D Blackwood D Reid IC Wolf CR Polymorphisms in the SLC6A4 and HTR2A genes influence treatment outcome following antidepressant therapyPharmacogenomics J2009 96170
Not in our library10.1038/sj.tpj.6500491
273.
McMahon FJ Buervenich S Charney D Lipsky R Rush AJ Wilson AF Sorant AJM Papanicolaou GJ Laje G Fava M Trivedi MH Wisniewski SR Manji H Variation in the gene encoding the serotonin 2A receptor is associated with outcome of antidepressant treatmentAm J Hum Genet2006 78804814
Not in our library10.1086/503820
274.
Murphy GM Jr Kremer C Rodrigues HE Schatzberg AF Pharmacogenetics of antidepressant medication intoleranceAm J Psychiatry2003 16018301835
Not in our library10.1176/appi.ajp.160.10.1830
275.
Illi A Setälä-Soikkeli E Viikki M Poutanen O Huhtala H Mononen N Lehtimäki T Leinonen E Kampman O 5-HTR1A, 5-HTR2A, 5-HTR6, TPH1 and TPH2 polymorphisms and major depressionNeuroreport2009 2011251128
Not in our library10.1097/wnr.0b013e32832eb708
276.
Tanaka M Kobayashi D Murakami Y Ozaki N Suzuki T Iwata N Haraguchi K Ieiri I Kinukawa N Hosoi M Ohtani H Sawada Y Mine K Genetic polymorphisms in the 5-hydroxytryptamine type 3B receptor gene and paroxetine-induced nauseaInt J Neuropsychopharmacol2008 11261267
Not in our library10.1017/s1461145707007985
277.
Sato K Yoshida K Takahashi H Ito K Kamata M Higuchi H Shimizu T Itoh K Inoue K Tezuka T Suzuki T Ohkubo T Sugawara K Otani K Association between -1438G/A promoter polymorphism in the 5-HT(2A) receptor gene and fluvoxamine response in Japanese patients with major depressive disorderNeuropsychobiology2002 46136140
Not in our library10.1159/000066394
278.
Binder EB Bradley RG Liu W Epstein MP Deveau TC Mercer KB Tang Y Gillespie CF Heim CM Nemeroff CB Schwartz AC Cubells JF Ressler KJ Association of FKBP5 polymorphisms and childhood abuse with risk of posttraumatic stress disorder symptoms in adultsJAMA2008 29912911305
Not in our library10.1001/jama.299.11.1291
279.
Velders FP Kuningas M Kumari M Dekker MJ Uitterlinden AG Kirschbaum C Hek K Hofman A Verhulst FC Kivimaki M Van Duijn CM Walker BR Tiemeier H Genetics of cortisol secretion and depressive symptoms: a candidate gene and genome wide association approachPsychoneuroendocrinology2011 3610531061
Not in our library10.1016/j.psyneuen.2011.01.003
280.
Kang JI Chung HC Jeung H-C Kim SJ An SK Namkoong K FKBP5 polymorphisms as vulnerability to anxiety and depression in patients with advanced gastric cancer: A controlled and prospective studyPsychoneuroendocrinology2012 3715691576
Not in our library10.1016/j.psyneuen.2012.02.017
281.
Binder EB Owens MJ Liu W Deveau TC Rush AJ Trivedi MH Fava M Bradley B Ressler KJ Nemeroff CB Association of polymorphisms in genes regulating the corticotropin-releasing factor system with antidepressant treatment responseArch Gen Psychiatry2010 67369379
Not in our library10.1001/archgenpsychiatry.2010.18
282.
Garriock HA Tanowitz M Kraft JB Dang VC Peters EJ Jenkins GD Reinalda MS McGrath PJ Von Zastrow M Slager SL Hamilton SP Association of mu-opioid receptor variants and response to citalopram treatment in major depressive disorderAm J Psychiatry2010 167565573
Not in our library10.1176/appi.ajp.2009.08081167
283.
Laje G Allen AS Akula N Manji H John Rush A McMahon FJ Genome-wide association study of suicidal ideation emerging during citalopram treatment of depressed outpatientsPharmacogenet Genomics2009 19666674
Not in our library10.1097/fpc.0b013e32832e4bcd
284.
Garriock HA Kraft JB Shyn SI Peters EJ Yokoyama JS Jenkins GD Reinalda MS Slager SL McGrath PJ Hamilton SP A genomewide association study of citalopram response in major depressive disorderBiol Psychiatry2010 67133138
Not in our library10.1016/j.biopsych.2009.08.029
285.
Ising M Lucae S Binder EB Bettecken T Uhr M Ripke S Kohli MA Hennings JM Horstmann S Kloiber S Menke A Bondy B Rupprecht R Domschke K Baune BT Arolt V Rush AJ Holsboer F Müller-Myhsok B A genomewide association study points to multiple loci that predict antidepressant drug treatment outcome in depressionArch Gen Psychiatry2009 66966975
Not in our library10.1001/archgenpsychiatry.2009.95
286.
Malhotra AK The Pharmacogenetics of Depression: Enter the GWASAm J Psychiatry2010 167493495
Not in our library10.1176/appi.ajp.2010.10020244
287.
Rybakowski JK Suwalska A Czerski PM Dmitrzak-Weglarz M Leszczynska-Rodziewicz A Hauser J Prophylactic effect of lithium in bipolar affective illness may be related to serotonin transporter genotypePharmacol Rep2005 57124127
Not in our library
288.
Masui T Hashimoto R Kusumi I Suzuki K Tanaka T Nakagawa S Kunugi H Koyama T A possible association between the -116C/G single nucleotide polymorphism of the XBP1 gene and lithium prophylaxis in bipolar disorderInt J Neuropsychopharmacol2006 98388
Not in our library10.1017/s1461145705005523
289.
Benedetti F Dallaspezia S Fulgosi MC Lorenzi C Serretti A Barbini B Colombo C Smeraldi E Actimetric evidence that CLOCK 3111 T/C SNP influences sleep and activity patterns in patients affected by bipolar depressionAm J Med Genet B Neuropsychiatr Genet2007 144B631635
Not in our library10.1002/ajmg.b.30475
290.
Rybakowski JK Suwalska A Skibinska M Dmitrzak-Weglarz M Leszczynska-Rodziewicz A Hauser J Response to lithium prophylaxis: interaction between serotonin transporter and BDNF genesAm J Med Genet B Neuropsychiatr Genet2007 144B820823
Not in our library10.1002/ajmg.b.30420
291.
Adli M Hollinde DL Stamm T Wiethoff K Tsahuridu M Kirchheiner J Heinz A Bauer M Response to lithium augmentation in depression is associated with the glycogen synthase kinase 3-beta -50T/C single nucleotide polymorphismBiol Psychiatry2007 6212951302
Not in our library10.1016/j.biopsych.2007.03.023
292.
Masui T Hashimoto R Kusumi I Suzuki K Tanaka T Nakagawa S Suzuki T Iwata N Ozaki N Kato T Takeda M Kunugi H Koyama T A possible association between missense polymorphism of the breakpoint cluster region gene and lithium prophylaxis in bipolar disorderProg Neuropsychopharmacol Biol Psychiatry2008 32204208
Not in our library10.1016/j.pnpbp.2007.08.010
293.
Mamdani F Alda M Grof P Young LT Rouleau G Turecki G Lithium response and genetic variation in the CREB family of genesAm J Med Genet B Neuropsychiatr Genet2008 147B500504
Not in our library10.1002/ajmg.b.30617
294.
Dmitrzak-Weglarz M Rybakowski JK Suwalska A Skibinska M Leszczynska-Rodziewicz A Szczepankiewicz A Hauser J Association studies of the BDNF and the NTRK2 gene polymorphisms with prophylactic lithium response in bipolar patientsPharmacogenomics2008 915951603
Not in our library10.2217/14622416.9.11.1595
295.
Arranz MJ De Leon J Pharmacogenetics and pharmacogenomics of schizophrenia: a review of last decade of researchMol Psychiatry2007 12707747
Not in our library10.1038/sj.mp.4002009
296.
Foster A Miller DD Buckley PF Pharmacogenetics and schizophreniaPsychiatr Clin North Am2007 30417435
Not in our library10.1016/j.psc.2007.04.004
297.
Nnadi CU Malhotra AK Individualizing antipsychotic drug therapy in schizophrenia: the promise of pharmacogeneticsCurr Psychiatry Rep2007 9313318
Not in our library10.1007/s11920-007-0038-2
298.
Reynolds GP The impact of pharmacogenetics on the development and use of antipsychotic drugsDrug Discov Today2007 12953959
Not in our library10.1016/j.drudis.2007.07.018
299.
Thelma B Srivastava V Tiwari AK Genetic underpinnings of tardive dyskinesia: passing the baton to pharmacogeneticsPharmacogenomics2008 912851306
Not in our library10.2217/14622416.9.9.1285
300.
Zai CC Romano-Silva MA Hwang R Zai GC Deluca V Müller DJ King N Voineskos AN Meltzer HY Lieberman JA Potkin SG Remington G Kennedy JL Genetic study of eight AKT1 gene polymorphisms and their interaction with DRD2 gene polymorphisms in tardive dyskinesiaSchizophr Res2008 106248252
Not in our library10.1016/j.schres.2008.08.036
301.
Steen VM Løvlie R MacEwan T McCreadie RG Dopamine D3-receptor gene variant and susceptibility to tardive dyskinesia in schizophrenic patientsMol Psychiatry1997 2139145
Not in our library10.1038/sj.mp.4000249
302.
Lerer B Segman RH Fangerau H Daly AK Basile VS Cavallaro R Aschauer HN McCreadie RG Ohlraun S Ferrier N Masellis M Verga M Scharfetter J Rietschel M Lovlie R Levy UH Meltzer HY Kennedy JL Steen VM Macciardi F Pharmacogenetics of tardive dyskinesia: combined analysis of 780 patients supports association with dopamine D3 receptor gene Ser9Gly polymorphismNeuropsychopharmacology2002 27105119
Not in our library10.1016/s0893-133x(02)00293-2
303.
Woo S Kim JW Rha E Han S Hahn K Park C Sohn J Association of the Ser9Gly polymorphism in the dopamine D3 receptor gene with tardive dyskinesia in Korean schizophrenicsPsychiatry Clin Neurosci2002 56469474
Not in our library10.1046/j.1440-1819.2002.01038.x
304.
Lieberman JA Stroup TS McEvoy JP Swartz MS Rosenheck RA Perkins DO Keefe RSE Davis SM Davis CE Lebowitz BD Severe J Hsiao JK Effectiveness of antipsychotic drugs in patients with chronic schizophreniaN Engl J Med2005 35312091223
Not in our library10.1056/nejmoa051688
305.
Tsai H-T North KE West SL Poole C The DRD3 rs6280 polymorphism and prevalence of tardive dyskinesia: a meta-analysisAm J Med Genet B Neuropsychiatr Genet2010 153B5766
Not in our library10.1002/ajmg.b.30946
306.
Bakker PR Van Harten PN Van Os J Antipsychotic-induced tardive dyskinesia and polymorphic variations in COMT, DRD2, CYP1A2 and MnSOD genes: a meta-analysis of pharmacogenetic interactionsMol Psychiatry2008 13544556
Not in our library10.1038/sj.mp.4002142
307.
Hori H Ohmori O Shinkai T Kojima H Okano C Suzuki T Nakamura J Manganese superoxide dismutase gene polymorphism and schizophrenia: relation to tardive dyskinesiaNeuropsychopharmacology2000 23170177
Not in our library10.1016/s0893-133x(99)00156-6
308.
Hitzeroth A Niehaus DJH Koen L Botes WC Deleuze JF Warnich L Association between the MnSOD Ala-9Val polymorphism and development of schizophrenia and abnormal involuntary movements in the Xhosa populationProg Neuropsychopharmacol Biol Psychiatry2007 31664672
Not in our library10.1016/j.pnpbp.2006.12.019
309.
Kang S-G Choi J-E An H Park Y-M Lee H-J Han C Kim Y-K Kim S-H Cho SN Joe S-H Jung I-K Kim L Lee M-S Manganese superoxide dismutase gene Ala-9Val polymorphism might be related to the severity of abnormal involuntary movements in Korean schizophrenic patientsProg Neuropsychopharmacol Biol Psychiatry2008 3218441847
Not in our library10.1016/j.pnpbp.2008.08.013
310.
Lerer B Segman RH Tan E-C Basile VS Cavallaro R Aschauer HN Strous R Chong S-A Heresco-Levy U Verga M Scharfetter J Meltzer HY Kennedy JL Macciardi F Combined analysis of 635 patients confirms an age-related association of the serotonin 2A receptor gene with tardive dyskinesia and specificity for the non-orofacial subtypeInt J Neuropsychopharmacol2005 8411425
Not in our library10.1017/s1461145705005389
311.
Zai CC Tiwari AK Basile V De Luca V Müller DJ Voineskos AN Remington G Meltzer HY Lieberman JA Potkin SG Kennedy JL Oxidative stress in tardive dyskinesia: genetic association study and meta-analysis of NADPH quinine oxidoreductase 1 (NQO1) and Superoxide dismutase 2 (SOD2, MnSOD) genesProg Neuropsychopharmacol Biol Psychiatry2010 345056
Not in our library10.1016/j.pnpbp.2009.09.020
312.
Boke O Gunes S Kara N Aker S Sahin AR Basar Y Bagci H Association of serotonin 2A receptor and lack of association of CYP1A2 gene polymorphism with tardive dyskinesia in a Turkish populationDNA Cell Biol2007 26527531
Not in our library10.1089/dna.2007.0605
313.
Allison DB Mentore JL Heo M Chandler LP Cappelleri JC Infante MC Weiden PJ Antipsychotic-induced weight gain: a comprehensive research synthesisAm J Psychiatry1999 15616861696
Not in our library10.1176/ajp.156.11.1686
314.
Henderson DC Cagliero E Gray C Nasrallah RA Hayden DL Schoenfeld DA Goff DC Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: A five-year naturalistic studyAm J Psychiatry2000 157975981
Not in our library10.1176/appi.ajp.157.6.975
315.
Müller DJ Kennedy JL Genetics of antipsychotic treatment emergent weight gain in schizophreniaPharmacogenomics2006 7863887
Not in our library10.2217/14622416.7.6.863
316.
Ryu S Cho EY Park T Oh S Jang W-S Kim S-K Lee D Hong KS 759 C/T polymorphism of 5-HT2C receptor gene and early phase weight gain associated with antipsychotic drug treatmentProg Neuropsychopharmacol Biol Psychiatry2007 31673677
Not in our library10.1016/j.pnpbp.2006.12.021
317.
Templeman LA Reynolds GP Arranz B San L Polymorphisms of the 5-HT2C receptor and leptin genes are associated with antipsychotic drug-induced weight gain in Caucasian subjects with a first-episode psychosisPharmacogenet Genomics2005 15195200
Not in our library10.1097/01213011-200504000-00002
318.
Reynolds GP The pharmacogenetics of symptom response to antipsychotic drugsPsychiatry Investig2012 917
Not in our library10.4306/pi.2012.9.1.1
319.
Zhang XY Tan YL Zhou DF Haile CN Cao LY Xu Q Shen Y Kosten TA Kosten TR Association of clozapine-induced weight gain with a polymorphism in the leptin promoter region in patients with chronic schizophrenia in a Chinese populationJ Clin Psychopharmacol2007 27246251
Not in our library10.1097/jcp.0b013e3180582412
320.
De Luca V Mueller DJ De Bartolomeis A Kennedy JL Association of the HTR2C gene and antipsychotic induced weight gain: a meta-analysisInt J Neuropsychopharmacol2007 10697704
Not in our library10.1017/s1461145707007547
321.
Sicard MN Zai CC Tiwari AK Souza RP Meltzer HY Lieberman JA Kennedy JL Müller DJ Polymorphisms of the HTR2C gene and antipsychotic-induced weight gain: an update and meta-analysisPharmacogenomics2010 1115611571
Not in our library10.2217/pgs.10.123
322.
Opgen-Rhein C Brandl EJ Müller DJ Neuhaus AH Tiwari AK Sander T Dettling M Association of HTR2C, but not LEP or INSIG2, genes with antipsychotic-induced weight gain in a German samplePharmacogenomics2010 11773780
Not in our library10.2217/pgs.10.50
323.
Kane J Honigfeld G Singer J Meltzer H Clozapine for the treatment-resistant schizophrenic, A double-blind comparison with chlorpromazineArch Gen Psychiatry1988 45789796
Not in our library10.1001/archpsyc.1988.01800330013001
324.
Alvir JM Lieberman JA A reevaluation of the clinical characteristics of clozapine-induced agranulocytosis in light of the United States experienceJ Clin Psychopharmacol1994 148789
Not in our library
325.
Chowdhury NI Remington G Kennedy JL Genetics of antipsychotic-induced side effects and agranulocytosisCurr Psychiatry Rep2011 13156165
Not in our library10.1007/s11920-011-0185-3
326.
Athanasiou MC Dettling M Cascorbi I Mosyagin I Salisbury BA Pierz KA Zou W Whalen H Malhotra AK Lencz T Gerson SL Kane JM Reed CR Candidate gene analysis identifies a polymorphism in HLA-DQB1 associated with clozapine-induced agranulocytosisJ Clin Psychiatry2011 72458463
Not in our library10.4088/jcp.09m05527yel
327.
Dettling M Cascorbi I Opgen-Rhein C Schaub R Clozapine-induced agranulocytosis in schizophrenic Caucasians: confirming clues for associations with human leukocyte class I and II antigensPharmacogenomics J2007 7325332
Not in our library10.1038/sj.tpj.6500423
328.
Need AC Keefe RSE Ge D Grossman I Dickson S McEvoy JP Goldstein DB Pharmacogenetics of antipsychotic response in the CATIE trial: a candidate gene analysisEur J Hum Genet2009 17946957
Not in our library10.1038/ejhg.2008.264
329.
McClay JL Adkins DE Aberg K Stroup S Perkins DO Vladimirov VI Lieberman JA Sullivan PF Van den Oord EJCG Genome-wide pharmacogenomic analysis of response to treatment with antipsychoticsMol Psychiatry2011 167685
Not in our library10.1038/mp.2009.89
330.
Huffaker SJ Chen J Nicodemus KK Sambataro F Yang F Mattay V Lipska BK Hyde TM Song J Rujescu D Giegling I Mayilyan K Proust MJ Soghoyan A Caforio G Callicott JH Bertolino A Meyer-Lindenberg A Chang J Ji Y Egan MF Goldberg TE Kleinman JE Lu B Weinberger DR A primate-specific, brain isoform of KCNH2 affects cortical physiology, cognition, neuronal repolarization and risk of schizophreniaNat Med2009 15509518
Not in our library10.1038/nm.1962
331.
Kongsamut S Kang J Chen X-L Roehr J Rampe D A comparison of the receptor binding and HERG channel affinities for a series of antipsychotic drugsEur J Pharmacol2002 4503741
Not in our library10.1016/s0014-2999(02)02074-5
332.
Apud JA Zhang F Decot H Bigos KL Weinberger DR Genetic variation in KCNH2 associated with expression in the brain of a unique hERG isoform modulates treatment response in patients with schizophreniaAm J Psychiatry2012 169725734
Not in our library10.1176/appi.ajp.2012.11081214
333.
Zhang J-P Lencz T Malhotra AK D2 receptor genetic variation and clinical response to antipsychotic drug treatment: a meta-analysisAm J Psychiatry2010 167763772
Not in our library10.1176/appi.ajp.2009.09040598
334.
Hwang R Zai C Tiwari A Müller DJ Arranz MJ Morris AG McKenna PJ Munro J Potkin SG Lieberman JA Meltzer HY Kennedy JL Effect of dopamine D3 receptor gene polymorphisms and clozapine treatment response: exploratory analysis of nine polymorphisms and meta-analysis of the Ser9Gly variantPharmacogenomics J2010 10200218
Not in our library10.1038/tpj.2009.65
335.
Schäfer M Rujescu D Giegling I Guntermann A Erfurth A Bondy B Möller HJ Association of short-term response to haloperidol treatment with a polymorphism in the dopamine D(2) receptor geneAm J Psychiatry2001 158802804
Not in our library10.1176/appi.ajp.158.5.802
336.
Ikeda M Yamanouchi Y Kinoshita Y Kitajima T Yoshimura R Hashimoto S O’Donovan MC Nakamura J Ozaki N Iwata N Variants of dopamine and serotonin candidate genes as predictors of response to risperidone treatment in first-episode schizophreniaPharmacogenomics2008 914371443
Not in our library10.2217/14622416.9.10.1437
337.
Shen Y-C Chen S-F Chen C-H Lin CCH Chen S-J Chen Y-J Luu S-U Effects of DRD2/ANKK1 gene variations and clinical factors on aripiprazole efficacy in schizophrenic patientsJ Psychiatr Res2009 43600606
Not in our library10.1016/j.jpsychires.2008.09.005
338.
Jönsson EG Flyckt L Burgert E Crocq M-A Forslund K Mattila-Evenden M Rylander G Asberg M Nimgaonkar VL Edman G Bjerkenstedt L Wiesel F-A Sedvall GC Dopamine D3 receptor gene Ser9Gly variant and schizophrenia: association study and meta-analysisPsychiatr Genet2003 13112
Not in our library10.1097/00041444-200303000-00001
339.
Binder EB Nemeroff CB Implications for the practice of psychiatryProgress in Brain Research2006 158275293
Not in our library10.1016/s0079-6123(06)58013-6
340.
De Leon J Pharmacogenomics: The Promise of Personalized Medicine for CNS DisordersNeuropsychopharmacology2008 34159172
Not in our library10.1038/npp.2008.147
341.
Bogdan R Hyde LW Hariri AR A neurogenetics approach to understanding individual differences in brain, behavior, and risk for psychopathologyMol Psychiatry2012 18288299
Not in our library10.1038/mp.2012.35
342.
Hanlon CA Jones EM Li X Hartwell KJ Brady KT George MS Individual variability in the locus of prefrontal craving for nicotine: Implications for brain stimulation studies and treatmentsDrug Alcohol Depend2012 125239243
Not in our library10.1016/j.drugalcdep.2012.02.019
343.
Hamilton JP Etkin A Furman DJ Lemus MG Johnson RF Gotlib IH Functional Neuroimaging of Major Depressive Disorder: A Meta-Analysis and New Integration of Baseline Activation and Neural Response DataAm J Psychiatry2012 169693703
Not in our library10.1176/appi.ajp.2012.11071105
344.
Johnson JS Hamidi M Postle BR Using EEG to explore how rTMS produces its effects on behaviorBrain Topogr2010 22281293
Not in our library10.1007/s10548-009-0118-1
345.
Etkin A Wager TD Functional neuroimaging of anxiety: a meta-analysis of emotional processing in PTSD, social anxiety disorder, and specific phobiaAm J Psychiatry2007 16414761488
Not in our library10.1176/appi.ajp.2007.07030504
346.
Frodl T Möller H-J Meisenzahl E Neuroimaging genetics: new perspectives in research on major depression?Acta Psychiatr Scand2008 118363372
Not in our library10.1111/j.1600-0447.2008.01225.x
347.
Thompson PM Martin NG Wright MJ Imaging genomicsCurr Opin Neurol2010 23368373
Not in our library10.1097/wco.0b013e32833b764c
348.
Marano CM Workman CI Kramer E Hermann CR Ma Y Dhawan V Chaly T Eidelberg D Smith GS Longitudinal studies of cerebral glucose metabolism in late-life depression and normal agingInt J Geriatr Psychiatry2013 28417423
Not in our library10.1002/gps.3840
349.
Neumeister A Normandin MD Murrough JW Henry S Bailey CR Luckenbaugh DA Tuit K Zheng M-Q Galatzer-Levy IR Sinha R Carson RE Potenza MN Huang Y Positron Emission Tomography Shows Elevated Cannabinoid CB (1) Receptor Binding in Men with Alcohol DependenceAlcohol Clin Exp Res2012 3621042109
Not in our library10.1111/j.1530-0277.2012.01815.x
350.
Nord M Farde L Antipsychotic occupancy of dopamine receptors in schizophreniaCNS Neurosci Ther2011 1797103
Not in our library10.1111/j.1755-5949.2010.00222.x
351.
Steele JD Currie J Lawrie SM Reid I Prefrontal cortical functional abnormality in major depressive disorder: a stereotactic meta-analysisJ Affect Disord2007 101111
Not in our library10.1016/j.jad.2006.11.009
352.
Campbell S Marriott M Nahmias C MacQueen GM Lower hippocampal volume in patients suffering from depression: a meta-analysisAm J Psychiatry2004 161598607
Not in our library10.1176/appi.ajp.161.4.598
353.
Videbech P Ravnkilde B Hippocampal volume and depression: a meta-analysis of MRI studiesAm J Psychiatry2004 16119571966
Not in our library10.1176/appi.ajp.161.11.1957
354.
Sheline YI Gado MH Kraemer HC Untreated depression and hippocampal volume lossAm J Psychiatry2003 16015161518
Not in our library10.1176/appi.ajp.160.8.1516
355.
Dannlowski U Ohrmann P Bauer J Deckert J Hohoff C Kugel H Arolt V Heindel W Kersting A Baune BT Suslow T 5-HTTLPR biases amygdala activity in response to masked facial expressions in major depressionNeuropsychopharmacology2008 33418424
Not in our library10.1038/sj.npp.1301411
356.
Dannlowski U Ohrmann P Bauer J Kugel H Baune BT Hohoff C Kersting A Arolt V Heindel W Deckert J Suslow T Serotonergic genes modulate amygdala activity in major depressionGenes Brain Behav2007 6672676
Not in our library10.1111/j.1601-183x.2006.00297.x
357.
Frodl T Meisenzahl EM Zill P Baghai T Rujescu D Leinsinger G Bottlender R Schüle C Zwanzger P Engel RR Rupprecht R Bondy B Reiser M Möller H-J Reduced hippocampal volumes associated with the long variant of the serotonin transporter polymorphism in major depressionArch Gen Psychiatry2004 61177183
Not in our library10.1001/archpsyc.61.2.177
358.
Taylor WD Steffens DC Payne ME MacFall JR Marchuk DA Svenson IK Krishnan KRR Influence of serotonin transporter promoter region polymorphisms on hippocampal volumes in late-life depressionArch Gen Psychiatry2005 62537544
Not in our library10.1001/archpsyc.62.5.537
359.
McDonald C Zanelli J Rabe-Hesketh S Ellison-Wright I Sham P Kalidindi S Murray RM Kennedy N Meta-analysis of magnetic resonance imaging brain morphometry studies in bipolar disorderBiol Psychiatry2004 56411417
Not in our library10.1016/j.biopsych.2004.06.021
360.
Kempton MJ Geddes JR Ettinger U Williams SCR Grasby PM Meta-analysis, database, and meta-regression of 98 structural imaging studies in bipolar disorderArch Gen Psychiatry2008 6510171032
Not in our library10.1001/archpsyc.65.9.1017
361.
Vita A De Peri L Sacchetti E Gray matter, white matter, brain, and intracranial volumes in first-episode bipolar disorder: a meta-analysis of magnetic resonance imaging studiesBipolar Disord2009 11807814
Not in our library10.1111/j.1399-5618.2009.00759.x
362.
Beyer JL Young R Kuchibhatla M Krishnan KRR Hyperintense MRI lesions in bipolar disorder: A meta-analysis and reviewInt Rev Psychiatry2009 21394409
Not in our library10.1080/09540260902962198
363.
Kempton MJ Salvador Z Munafò MR Geddes JR Simmons A Frangou S Williams SCR Structural neuroimaging studies in major depressive disorder. Meta-analysis and comparison with bipolar disorderArch Gen Psychiatry2011 68675690
Not in our library10.1001/archgenpsychiatry.2011.60
364.
Houenou J Frommberger J Carde S Glasbrenner M Diener C Leboyer M Wessa M Neuroimaging-based markers of bipolar disorder: evidence from two meta-analysesJ Affect Disord2011 132344355
Not in our library10.1016/j.jad.2011.03.016
365.
Hajek T Kopecek M Kozeny J Gunde E Alda M Höschl C Amygdala volumes in mood disorders–meta-analysis of magnetic resonance volumetry studiesJ Affect Disord2009 115395410
Not in our library10.1016/j.jad.2008.10.007
366.
Pfeifer JC Welge J Strakowski SM Adler CM DelBello MP Meta-analysis of amygdala volumes in children and adolescents with bipolar disorderJ Am Acad Child Adolesc Psychiatry2008 4712891298
Not in our library10.1097/chi.0b013e318185d299
367.
Davidson LL Heinrichs RW Quantification of frontal and temporal lobe brain-imaging findings in schizophrenia: a meta-analysisPsychiatry Res2003 1226987
Not in our library10.1016/s0925-4927(02)00118-x
368.
Hill K Mann L Laws KR Stephenson CME Nimmo-Smith I McKenna PJ Hypofrontality in schizophrenia: a meta-analysis of functional imaging studiesActa Psychiatr Scand2004 110243256
Not in our library10.1111/j.1600-0447.2004.00376.x
369.
Raz S Raz N Structural brain abnormalities in the major psychoses: a quantitative review of the evidence from computerized imagingPsychol Bull1990 10893108
Not in our library10.1037/0033-2909.108.1.93
370.
Boos HBM Aleman A Cahn W Hulshoff Pol H Kahn RS Brain volumes in relatives of patients with schizophrenia: a meta-analysisArch Gen Psychiatry2007 64297304
Not in our library10.1001/archpsyc.64.3.297
371.
Zakzanis KK Hansen KT Dopamine D2 densities and the schizophrenic brainSchizophr Res1998 32201206
Not in our library10.1016/s0920-9964(98)00041-3
372.
Olabi B Ellison-Wright I McIntosh AM Wood SJ Bullmore E Lawrie SM Are there progressive brain changes in schizophrenia? A meta-analysis of structural magnetic resonance imaging studiesBiol Psychiatry2011 708896
Not in our library10.1016/j.biopsych.2011.01.032
373.
Shepherd AM Laurens KR Matheson SL Carr VJ Green MJ Systematic meta-review and quality assessment of the structural brain alterations in schizophreniaNeurosci Biobehav Rev2012 3613421356
Not in our library10.1016/j.neubiorev.2011.12.015
374.
Nelson MD Saykin AJ Flashman LA Riordan HJ Hippocampal volume reduction in schizophrenia as assessed by magnetic resonance imaging: a meta-analytic studyArch Gen Psychiatry1998 55433440
Not in our library10.1001/archpsyc.55.5.433
375.
Steen RG Mull C McClure R Hamer RM Lieberman JA Brain volume in first-episode schizophrenia: systematic review and meta-analysis of magnetic resonance imaging studiesBr J Psychiatry2006 188510518
Not in our library10.1192/bjp.188.6.510
376.
Adriano F Caltagirone C Spalletta G Hippocampal volume reduction in first-episode and chronic schizophrenia: a review and meta-analysisNeuroscientist2012 18180200
Not in our library10.1177/1073858410395147
377.
Baig BJ Whalley HC Hall J McIntosh AM Job DE Cunningham-Owens DG Johnstone EC Lawrie SM Functional magnetic resonance imaging of BDNF val66met polymorphism in unmedicated subjects at high genetic risk of schizophrenia performing a verbal memory taskPsychiatry Res2010 183195201
Not in our library10.1016/j.pscychresns.2010.06.009
378.
Van Zuiden M Geuze E Willemen HLDM Vermetten E Maas M Heijnen CJ Kavelaars A Pre-existing high glucocorticoid receptor number predicting development of posttraumatic stress symptoms after military deploymentAm J Psychiatry2011 1688996
Not in our library10.1176/appi.ajp.2010.10050706
379.
Gatt JM Williams LM Schofield PR Dobson-Stone C Paul RH Grieve SM Clark CR Gordon E Nemeroff CB Impact of the HTR3A gene with early life trauma on emotional brain networks and depressed moodDepress Anxiety2010 27752759
Not in our library10.1002/da.20726
380.
Murphy KC Jones LA Owen MJ High rates of schizophrenia in adults with velo-cardio-facial syndromeArch Gen Psychiatry1999 56940945
Not in our library10.1001/archpsyc.56.10.940
381.
Dunbar L Butler R Wheeler A Pulford J Miles W Sheridan J Clinician experiences of employing the AmpliChip® CYP450 test in routine psychiatric practiceJ Psychopharmacol (Oxford)2012 26390397
Not in our library10.1177/0269881109106957

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.